



ACPE Accredited Provider

#0122


Annual Pharmacy CE Summary Report

CE Activities of 2024

Report Contents

| | |
|---|----|
| Premier CE Program Participation | 3 |
| Summary of CE Hours Provided in 2024 | 4 |
| 2024 Evaluation Scoring Reports | |
| CE Teleconference Evaluations Report – Pharmacists | 5 |
| CE Teleconference Evaluations Report – Pharmacy Technicians | 6 |
| Antimicrobial Stewardship Forum Evaluations Reports..... | 7 |
| Pharmacy Practice Forum Evaluations Reports | 8 |
| Home-Study CE Evaluations Report – Pharmacists | 9 |
| Home-Study CE Evaluations Report – Pharmacy Technicians | 11 |
| Breakthroughs CE Evaluations Report – Pharmacists Only..... | 13 |
| Other Live CE Evaluations Reports | 14 |
| 2024 CE Comments Reports | |
| CE Teleconference Comments Report - Pharmacists..... | 15 |
| CE Teleconference Comments Report – Pharmacy Technicians..... | 16 |
| Antimicrobial Stewardship Forum Comments Reports..... | 17 |
| Pharmacy Practice Forum Comments Reports..... | 18 |
| Home-Study CE Comments Report - Pharmacists..... | 19 |
| Home-Study CE Comments Report – Pharmacy Technicians..... | 21 |
| Breakthroughs CE Comments Report..... | 23 |
| Other Live CE Comments Reports..... | 24 |
| 2024 Overall CE Activity Ratings | 25 |

Premier CE Program Participation



Averages for 2024 CE activities (numbers are averages per CE activity based on annual registration and CE completion):

- **Monthly CE Webinars: 671 registrants; 501 completed CE requirements**
- **Pharmacy Practice Forum: 636 registrants; 468 completed CE requirements**
- **Antimicrobial Stewardship Forum: 632 registrants; 489 completed CE requirements**

Premier Member Meeting live CE totals in Dec 2024: 21 registrants; 21 completed CE requirements

Home-study CEs: 34 activities offered; average of 173 registrants each; average of 119 CE recipients each

Summary of CE Hours Provided in 2024

| |
|---|
| Total Number of Live CE Activities Offered |
| 38 |
| Total Hours of Live CE Offered |
| 37 |
| Total Number of Home-Study CE Activities Offered |
| 34 |
| Hours of Home-study CE Offered |
| 34 |
| Hours of CE Offered to Pharmacists (Live + Home-study) |
| 71 |
| Hours of CE Offered to Pharmacy Technicians (Live + Home-study) |
| 70 |
| Active Learning Strategies Used in CE Activities |
| Polling questions; case discussions; Q&A with speaker |

Premier, Inc.
CE Teleconference Evaluations Report - Pharmacists
2024

| Date and Working Program Title | Speaker Name, e-mail address | Credit Hrs | Total # of Registrants | Total # of CE Recipients | # of Pharmacists Receiving CE | Objectives were met | Activity met educational needs | Quality of faculty was satisfactory | Educational materials were useful | Teaching methods were effective | Learning assessment activities were appropriate | Actively participated in activity | Activity did not promote product or company | Overall Activity Rating | Specialty Areas | Focus Areas (Outcomes, Safety, Best Practices) |
|---|--|------------|------------------------|--------------------------|-------------------------------|---------------------|--------------------------------|-------------------------------------|-----------------------------------|---------------------------------|---|-----------------------------------|---|-------------------------|--------------------------|--|
| January 30, 2024: Adalimumab-SOS: Navigating the Market Entry of Adalimumab Biosimilars in the US | Stefanie Cisek, PharmD, BCACP; stefanie.cisek@nm.org | 1.0 | 590 | 459 | 387 | 4.4 | 4.38 | 4.41 | 4.4 | 4.39 | 4.38 | 4.36 | 4.43 | 4.39 | Disease State Management | Best Practices |
| February 20, 2024: Medication Management of Parkinson's disease (PD) and Sequelae | Jacquelyn Bainbridge PharmD, FCCP; jacci.bainbridge@cuanschutz.edu | 1.0 | 662 | 490 | 422 | 4.44 | 4.44 | 4.46 | 4.44 | 4.44 | 4.45 | 4.41 | 4.47 | 4.44 | Disease State Management | Best Practices |
| March 20, 2024: What Lies Ahead – A Look at the Biosimilar, Infectious Diseases and Specialty/Oncology Drug Pipeline in 2024-2025 | Liya Davydov, PharmD, BCPS, BCGP; liya_davydov@premierinc.com | 1.0 | 679 | 510 | 428 | 4.34 | 4.32 | 4.34 | 4.34 | 4.32 | 4.33 | 4.32 | 4.4 | 4.34 | Disease State Management | Best Practices |
| April 24, 2024: Buprenorphine in the Management of Opioid Use Disorder (OUD): Updates on Role in Therapy, Accessibility, and Novel Dosing Strategies | Michael Biglow, PharmD, BCPS, BCPP; mbiglow@phs.org | 1.0 | 682 | 493 | 424 | 4.48 | 4.46 | 4.48 | 4.47 | 4.47 | 4.45 | 4.43 | 4.48 | 4.47 | Pain Management | Best Practices |
| May 22, 2024: Cultivating an Inclusive Culture: Managing Difficult Co-Workers Including Yourself | Kevin N. Hansen, PharmD, MS, BCSCP; kevin.hansen@premierinc.com | 1.0 | 675 | 492 | 409 | 4.47 | 4.47 | 4.49 | 4.47 | 4.46 | 4.46 | 4.44 | 4.51 | 4.47 | Pharmacy Administration | Best Practices |
| | Robert P. Granko, PharmD, MBA, FASHP, FNCAAP; rgranko@pennstatehealth.psu.edu | | | | | | | 4.49 | | | | | | | | |
| June 26, 2024: Protecting Our Little Ones! Reducing Medication Errors in Neonates and Pediatrics | Judith Scala, PharmD, BCPPS; JScala@saintpetersuh.com | 1.0 | 886 | 632 | 541 | 4.49 | 4.48 | 4.5 | 4.46 | 4.48 | 4.48 | 4.46 | 4.5 | 4.48 | Patient Safety | Safety |
| July 24, 2024: Updates GLP-1 & GIP Agonists for Weight Loss | Melissa Lipari, PharmD, BCACP; mlipari@wayne.edu | 1.0 | 693 | 518 | 445 | 4.49 | 4.47 | 4.49 | 4.48 | 4.48 | 4.48 | 4.45 | 4.49 | 4.48 | Disease State Management | Best Practices |
| | Pramodini Kale-Pradhan, PharmD, FCCP), FIDSA ; pkale@wayne.edu | | | | | | | 4.49 | | | | | | | | |
| | Alison Lobkovich, PharmD; alison.lobkovich@wayne.edu | | | | | | | 4.49 | | | | | | | | |
| August 21, 2024: Optimizing Pharmaceutical Distribution Management: Strategies for Price Transparency and Wholesaler Relations | Mohammed Abdulwahhab; madbulwahhab@mhs.net | 1.0 | 511 | 393 | 325 | 4.4 | 4.38 | 4.42 | 4.38 | 4.38 | 4.4 | 4.4 | 4.43 | 4.40 | Pharmacy Administration | Best Practices |
| | Kyle Brauer; Kyle.Brauer@baycare.org | | | | | | | 4.42 | | | | | | | | |
| September 17, 2024: The Future is Now: The Impact of Artificial Intelligence on Medication Use Safety | Steven Smoke, PharmD, BCIDP; Steven.Smoke@rwjh.org | 1.0 | 772 | 593 | 507 | 4.43 | 4.41 | 4.44 | 4.4 | 4.41 | 4.41 | 4.41 | 4.45 | 4.42 | Patient Safety | Safety |
| | Daniel T. Abazia, PharmD, BCPS, CPPS; dabazia@pharmacy.rutgers.edu | | | | | | | 4.45 | | | | | | | | |
| October 24, 2024: Multiple Sclerosis: Overview and Advances in Treatment | Mitra Habibi, PharmD; mhabib1@uic.edu | 1.0 | 652 | 504 | 416 | 4.45 | 4.44 | 4.45 | 4.45 | 4.43 | 4.44 | 4.43 | 4.47 | 4.45 | Disease State Management | Best Practices |
| November 20, 2024: Leading Analytics Strategy to Support the Enterprise | David Aguero, PharmD, MSTL, FASHP, FAMA; david.aguero@stjude.org | 1.0 | 660 | 489 | 408 | 4.44 | 4.41 | 4.42 | 4.41 | 4.4 | 4.43 | 4.41 | 4.46 | 4.42 | Pharmacy Administration | Best Practices |
| December 18, 2024: A Gene Therapy Primer for Health Systems | Blake Shay, PharmD, MS; Blake.Shay@baycare.org (blakeshay2014@gmail.com) | 1.0 | 591 | 439 | 368 | 4.4 | 4.4 | 4.39 | 4.38 | 4.39 | 4.39 | 4.36 | 4.41 | 4.39 | Disease State Management | Best Practices |

Premier, Inc.
CE Teleconference Evaluations Report - Pharmacy Technicians
2024

| Date and Working Program Title | Speaker Name, e-mail address | Credit Hrs | Total # of Registrants | Total # of CE Recipients | # of Pharmacy Technicians Receiving CE | Objectives were met | Activity met educational needs | Quality of faculty was satisfactory | Educational materials were useful | Teaching methods were effective | Learning assessment activities were appropriate | Actively participated in activity | Activity did not promote product or company | Overall Activity Rating | Specialty Areas | Focus Areas (Outcomes, Safety, Best Practices) |
|---|--|------------|------------------------|--------------------------|--|---------------------|--------------------------------|-------------------------------------|-----------------------------------|---------------------------------|---|-----------------------------------|---|-------------------------|--------------------------|--|
| January 30, 2024: Adalimumab-SOS: Navigating the Market Entry of Adalimumab Biosimilars in the US | Stefanie Cisek, PharmD, BCACP; stefanie.cisek@nm.org | 1.0 | 590 | 459 | 72 | 4.41 | 4.41 | 4.4 | 4.39 | 4.41 | 4.41 | 4.35 | 4.4 | 4.40 | Disease State Management | Best Practices |
| February 20, 2024: Medication Management of Parkinson's disease (PD) and Sequelae | Jacquelyn Bainbridge PharmD, FCCP; jacci.bainbridge@cuanschutz.edu | 1.0 | 662 | 490 | 68 | 4.38 | 4.39 | 4.38 | 4.35 | 4.35 | 4.36 | 4.32 | 4.38 | 4.36 | Disease State Management | Best Practices |
| March 20, 2024: What Lies Ahead – A Look at the Biosimilar, Infectious Diseases and Specialty/Oncology Drug Pipeline in 2024-2025 | Liya Davydov, PharmD, BCPS, BCGP; liya_davydov@premierinc.com | 1.0 | 679 | 510 | 82 | 4.46 | 4.39 | 4.42 | 4.4 | 4.45 | 4.39 | 4.42 | 4.41 | 4.42 | Disease State Management | Best Practices |
| April 24, 2024: Buprenorphine in the Management of Opioid Use Disorder (OUD): Updates on Role in Therapy, Accessibility, and Novel Dosing Strategies | Michael Biglow, PharmD, BCPS, BCPP; mbiglow@pfs.org | 1.0 | 682 | 493 | 69 | 4.33 | 4.33 | 4.29 | 4.33 | 4.35 | 4.32 | 4.28 | 4.33 | 4.32 | Pain Management | Best Practices |
| May 22, 2024: Cultivating an Inclusive Culture: Managing Difficult Co-Workers Including Yourself | Kevin N. Hansen, PharmD, MS, BCSCP; kevin.hansen@premierinc.com | 1.0 | 675 | 492 | 83 | 4.33 | 4.34 | 4.30 | 4.34 | 4.35 | 4.28 | 4.28 | 4.33 | 4.31 | Pharmacy Administration | Best Practices |
| | 4.28 | | | | | | | | | | | | | | | |
| June 26, 2024: Protecting Our Little Ones! Reducing Medication Errors in Neonates and Pediatrics | Judith Scala, PharmD, BCPPS; JScala@saintpetersuh.com | 1.0 | 886 | 632 | 91 | 4.48 | 4.45 | 4.5 | 4.47 | 4.46 | 4.42 | 4.34 | 4.45 | 4.45 | Patient Safety | Safety |
| July 24, 2024: Updates GLP-1 & GIP Agonists for Weight Loss | Melissa Lipari, PharmD, BCACP; mlipari@wayne.edu | 1.0 | 693 | 518 | 73 | 4.4 | 4.36 | 4.41 | 4.34 | 4.4 | 4.38 | 4.37 | 4.4 | 4.38 | Disease State Management | Best Practices |
| | Pramodini Kale-Pradhan, PharmD, FCCP, FIDSA; pkale@wayne.edu | | | | | | | | | | | | | | | |
| | Alison Lobkovich, PharmD; alison.lobkovich@wayne.edu | | | | | | | | | | | | | | | |
| August 21, 2024: Optimizing Pharmaceutical Distribution Management: Strategies for Price Transparency and Wholesaler Relations | Mohammed Abdulwahhab; madbulwahhab@mhs.net | 1.0 | 511 | 393 | 68 | 4.35 | 4.31 | 4.31 | 4.27 | 4.3 | 4.34 | 4.21 | 4.2 | 4.29 | Pharmacy Administration | Best Practices |
| | Kyle Brauer; Kyle.Brauer@baycare.org | | | | | | | | | | | | | | | |
| September 17, 2024: The Future is Now: The Impact of Artificial Intelligence on Medication Use Safety | Steven Smoke, PharmD, BCIDP; Steven.Smoke@rwibh.org | 1.0 | 772 | 593 | 86 | 4.41 | 4.41 | 4.42 | 4.43 | 4.41 | 4.41 | 4.34 | 4.4 | 4.41 | Patient Safety | Safety |
| | Daniel T. Abazia, PharmD, BCPS, CPPS; dabazia@pharmacy.rutgers.edu | | | | | | | | | | | | | | | |
| October 24, 2024: Multiple Sclerosis: Overview and Advances in Treatment | Mitra Habibi, PharmD; mhabib1@uic.edu | 1.0 | 652 | 504 | 88 | 4.42 | 4.35 | 4.34 | 4.34 | 4.42 | 4.39 | 4.26 | 4.39 | 4.36 | Disease State Management | Best Practices |
| November 20, 2024: Leading Analytics Strategy to Support the Enterprise | David Aguero, PharmD, MSTL, FASHP, FAMILA; david.aguero@stjude.org | 1.0 | 660 | 489 | 81 | 4.4 | 4.41 | 4.44 | 4.33 | 4.4 | 4.39 | 4.35 | 4.39 | 4.39 | Pharmacy Administration | Best Practices |
| December 18, 2024: A Gene Therapy Primer for Health Systems | Blake Shay, PharmD, MS; Blake.Shay@baycare.org (blakeshay2014@gmail.com) | 1.0 | 591 | 439 | 71 | 4.46 | 4.46 | 4.49 | 4.46 | 4.49 | 4.5 | 4.46 | 4.49 | 4.48 | Disease State Management | Best Practices |

Premier, Inc.
Antimicrobial Stewardship Forum Evaluations Reports
2024

Pharmacists

| Date and Working Program Title | Speaker Name, e-mail address | Credit Hrs | Total # of Registrants | Total # of CE Recipients | # of Pharmacists Receiving CE | Objectives were met | Activity met educational needs | Quality of faculty was satisfactory | Educational materials were useful | Teaching methods were effective | Learning assessment activities were appropriate | Actively participated in activity | Activity did not promote product or company | Overall Activity Rating | Specialty Areas | Focus Areas (Outcomes, Safety, Best Practices) |
|---|--|------------|------------------------|--------------------------|-------------------------------|---------------------|--------------------------------|-------------------------------------|-----------------------------------|---------------------------------|---|-----------------------------------|---|-------------------------|--------------------------|--|
| February 7, 2024: NHSN Antibiotic Use Option Data: Implementation and Strategies for Use | Christopher Evans, PharmD; christopher.evans@tn.gov | 1.0 | 660 | 487 | 424 | 4.39 | 4.37 | 4.4 | 4.38 | 4.38 | 4.39 | 4.38 | 4.44 | 4.39 | Pharmacy Administration | Best Practices |
| April 3, 2024: Sustaining Antimicrobial Stewardship Strategies in Suspected Sepsis | Jeffrey Pearson, PharmD, BCIDP; jpearson@bwh.harvard.edu | 1.0 | 649 | 473 | 405 | 4.52 | 4.54 | 4.53 | 4.53 | 4.52 | 4.52 | 4.47 | 4.55 | 4.52 | Disease State Management | Best Practices |
| June 4, 2024: Therapeutics for Respiratory Syncytial Virus: How Far We've Come | Christine R. Lockowitz, Pharm.D., BCIDP; Christine.Hanks@bjc.org | 1.0 | 654 | 485 | 417 | 4.45 | 4.47 | 4.48 | 4.48 | 4.46 | 4.46 | 4.46 | 4.5 | 4.47 | Disease State Management | Best Practices |
| August 8, 2024: From Concept to Implementation: Developing an Outpatient Antimicrobial Stewardship Program at Intermountain Health | Whitney Buckel, PharmD, BCIDP; Whitney.Buckel@imail.org | 1.0 | 605 | 441 | 371 | 4.42 | 4.42 | 4.44 | 4.4 | 4.41 | 4.42 | 4.4 | 4.45 | 4.42 | Disease State Management | Best Practices |
| | Allan Seibert, MD; allan.seibert@imail.org | | | | | | | 4.45 | | | | | | | | |
| October 1, 2024: Yes We Can(dida): Approaches to Invasive Candidiasis and Antifungal Stewardship | Caleb Rux, PharmD, BCIDP; calebrux@gmail.com | 1.0 | 635 | 503 | 428 | 4.51 | 4.5 | 4.51 | 4.5 | 4.5 | 4.51 | 4.49 | 4.54 | 4.51 | Disease State Management | Best Practices |
| December 11, 2024: Understanding and Managing C. difficile infection: Pathogenesis, Treatment, and Recurrence Prevention | Emily Drwiega, PharmD, BCIDP, BCPS, AAHIVP; edrwiega@uic.edu | 1.0 | 591 | 542 | 449 | 4.49 | 4.48 | 4.47 | 4.47 | 4.46 | 4.47 | 4.44 | 4.5 | | Disease State Management | Best Practices |

Pharmacy Technicians

| Date and Working Program Title | Speaker Name, e-mail address | Credit Hrs | Total # of Registrants | Total # of CE Recipients | # of Pharmacy Techs Receiving CE | Objectives were met | Activity met educational needs | Quality of faculty was satisfactory | Educational materials were useful | Teaching methods were effective | Learning assessment activities were appropriate | Actively participated in activity | Activity did not promote product or company | Overall Activity Rating | Specialty Areas | Focus Areas (Outcomes, Safety, Best Practices) |
|---|--|------------|------------------------|--------------------------|----------------------------------|---------------------|--------------------------------|-------------------------------------|-----------------------------------|---------------------------------|---|-----------------------------------|---|-------------------------|--------------------------|--|
| February 7, 2024: NHSN Antibiotic Use Option Data: Implementation and Strategies for Use | Christopher Evans, PharmD; christopher.evans@tn.gov | 1.0 | 660 | 487 | 63 | 4.39 | 4.38 | 4.38 | 4.36 | 4.38 | 4.39 | 4.35 | 4.35 | 4.37 | Pharmacy Administration | Best Practices |
| April 3, 2024: Sustaining Antimicrobial Stewardship Strategies in Suspected Sepsis | Jeffrey Pearson, PharmD, BCIDP; jpearson@bwh.harvard.edu | 1.0 | 649 | 473 | 68 | 4.39 | 4.41 | 4.43 | 4.38 | 4.41 | 4.48 | 4.38 | 4.43 | 4.41 | Disease State Management | Best Practices |
| June 4, 2024: Therapeutics for Respiratory Syncytial Virus: How Far We've Come | Christine R. Lockowitz, Pharm.D., BCIDP; Christine.Hanks@bjc.org | 1.0 | 654 | 485 | 68 | 4.5 | 4.25 | 4.00 | 4.25 | 4.25 | 4.00 | 4.5 | 4.25 | 4.25 | Disease State Management | Best Practices |
| August 8, 2024: From Concept to Implementation: Developing an Outpatient Antimicrobial Stewardship Program at Intermountain Health | Whitney Buckel, PharmD, BCIDP; Whitney.Buckel@imail.org | 1.0 | 605 | 441 | 70 | 4.38 | 4.3 | 4.35 | 4.36 | 4.33 | 4.3 | 4.22 | 4.35 | 4.33 | Disease State Management | Best Practices |
| | Allan Seibert, MD; allan.seibert@imail.org | | | | | | | 4.35 | | | | | | | | |
| October 1, 2024: Yes We Can(dida): Approaches to Invasive Candidiasis and Antifungal Stewardship | Caleb Rux, PharmD, BCIDP; calebrux@gmail.com | 1.0 | 635 | 503 | 75 | 4.4 | 4.31 | 4.35 | 4.35 | 4.35 | 4.35 | 4.27 | 4.37 | 4.34 | Disease State Management | Best Practices |
| December 11, 2024: Understanding and Managing C. difficile infection: Pathogenesis, Treatment, and Recurrence Prevention | Emily Drwiega, PharmD, BCIDP, BCPS, AAHIVP; edrwiega@uic.edu | 1.0 | 591 | 542 | 93 | 4.44 | 4.42 | 4.43 | 4.41 | 4.43 | 4.43 | 4.34 | 4.41 | | Disease State Management | Best Practices |

Premier, Inc.
Pharmacy Practice Forum Evaluations Reports
2024

Pharmacists

| Date and Working Program Title | Speaker Name, e-mail address | Credit Hrs | Total # of Registrants | Total # of CE Recipients | # of Pharmacists Receiving CE | Objectives were met | Activity met educational needs | Quality of faculty was satisfactory | Educational materials were useful | Teaching methods were effective | Learning assessment activities were appropriate | Actively participated in activity | Activity did not promote a product or company | Overall Activity Rating | Specialty Areas | Focus Areas (Outcomes, Safety, Best Practices) |
|---|--|------------|------------------------|--------------------------|-------------------------------|---------------------|--------------------------------|-------------------------------------|-----------------------------------|---------------------------------|---|-----------------------------------|---|-------------------------|--------------------------|--|
| January 10, 2024: Outsourcing to 503Bs: Ingredients, Methods, and Strategies | Kevin N. Hansen, PharmD, MS, BCSCP; kevin.hansen@premierinc.com | 1.0 | 634 | 471 | 409 | 4.45 | 4.44 | 4.46 | 4.45 | 4.45 | 4.45 | 4.43 | 4.48 | 4.45 | Compounding | Best Practices |
| March 7, 2024: What's New with New Technology Add-On Payments? | Alison Schlang, PharmD, MBA, BCPS, FACHE; alison_schlang@premierinc.com | 1.0 | 528 | 383 | 323 | 4.40 | 4.32 | 4.36 | 4.35 | 4.34 | 4.33 | 4.30 | 4.39 | 4.35 | Pharmacy Administration | Best Practices |
| May 1, 2024: Pharmacy Considerations for the Optimal Utilization of T-cell Engaging Bispecific Antibodies for Hematologic Malignancies | Donald Moore, PharmD, BCPS, BCOP, DPLA, FCCP ; Donald.Moore1@atriumhealth.org | 1.0 | 547 | 410 | 32 | 4.42 | 4.44 | 4.42 | 4.42 | 4.42 | 4.42 | 4.38 | 4.43 | 4.42 | Disease State Management | Best Practices |
| July 10, 2024: The Evolution of Pharmacist Responsibility | Peter P. Cohron, BSPharm, JD; pharmacylawsourc@gmail.com | 1.0 | 689 | 507 | 451 | 4.51 | 4.49 | 4.50 | 4.48 | 4.48 | 4.49 | 4.47 | 4.54 | 4.50 | Pharmacy Law | Best Practices |
| September 24, 2024: Rx Resilience: Health System Strategies to Bolster the Pharmacy Supply Chain and Safeguard Reimbursement | Tyler Sledge, PharmD, BCPS; Tyler.Sledge@rivhs.com Leah West; Leah.West@rivhs.com | 1.0 | 594 | 459 | 386 | 4.42 | 4.39 | 4.41 4.41 | 4.39 | 4.38 | 4.4 | 4.38 | 4.43 | 4.40 | Pharmacy Administration | Best Practices |
| November 12, 2024: Sterile Compounding Compliance Tips for Inspections and Surveys | Patricia C. Kienle, RPh, MPA, BCSCP, FASHP; patricia.kienle@cardinal.com | 1.0 | 826 | 579 | 489 | 4.43 | 4.43 | 4.45 | 4.41 | 4.42 | 4.42 | 4.41 | 4.48 | 4.43 | Compounding | Best Practices |

Pharmacy Technicians

| Date and Working Program Title | Speaker Name, e-mail address | Credit Hrs | Total # of Registrants | Total # of CE Recipients | # of Pharmacy Techs Receiving CE | Objectives were met | Activity met educational needs | Quality of faculty was satisfactory | Educational materials were useful | Teaching methods were effective | Learning assessment activities were appropriate | Actively participated in activity | Activity did not promote a product or company | Overall Activity Rating | Specialty Areas | Focus Areas (Outcomes, Safety, Best Practices) |
|---|--|------------|------------------------|--------------------------|----------------------------------|---------------------|--------------------------------|-------------------------------------|-----------------------------------|---------------------------------|---|-----------------------------------|---|-------------------------|--------------------------|--|
| January 10, 2024: Outsourcing to 503Bs: Ingredients, Methods, and Strategies | Kevin N. Hansen, PharmD, MS, BCSCP; kevin.hansen@premierinc.com | 1.0 | 634 | 471 | 62 | 4.50 | 4.47 | 4.53 | 4.52 | 4.45 | 4.53 | 4.44 | 4.48 | 4.49 | Compounding | Best Practices |
| March 7, 2024: What's New with New Technology Add-On Payments? | Alison Schlang, PharmD, MBA, BCPS, FACHE; alison_schlang@premierinc.com | 1.0 | 528 | 383 | 60 | 4.33 | 4.37 | 4.43 | 4.45 | 4.30 | 4.38 | 4.30 | 4.30 | 4.36 | Pharmacy Administration | Best Practices |
| May 1, 2024: Pharmacy Considerations for the Optimal Utilization of T-cell Engaging Bispecific Antibodies for Hematologic Malignancies | Donald Moore, PharmD, BCPS, BCOP, DPLA, FCCP ; Donald.Moore1@atriumhealth.org | 1.0 | 547 | 410 | 68 | 4.36 | 4.29 | 4.33 | 4.31 | 4.29 | 4.30 | 4.30 | 4.29 | 4.31 | Disease State Management | Best Practices |
| July 10, 2024: The Evolution of Pharmacist Responsibility | Peter P. Cohron, BSPharm, JD; pharmacylawsourc@gmail.com | 1.0 | 689 | 507 | 56 | 4.39 | 4.38 | 4.41 | 4.39 | 4.39 | 4.39 | 4.34 | 4.34 | 4.38 | Pharmacy Law | Best Practices |
| September 24, 2024: Rx Resilience: Health System Strategies to Bolster the Pharmacy Supply Chain and Safeguard Reimbursement | Tyler Sledge, PharmD, BCPS; Tyler.Sledge@rivhs.com Leah West; Leah.West@rivhs.com | 1.0 | 594 | 459 | 73 | 4.37 | 4.32 | 4.32 4.31 | 4.31 | 4.35 | 4.33 | 4.27 | 4.32 | 4.32 | Pharmacy Administration | Best Practices |
| November 12, 2024: Sterile Compounding Compliance Tips for Inspections and Surveys | Patricia C. Kienle, RPh, MPA, BCSCP, FASHP; patricia.kienle@cardinal.com | 1.0 | 826 | 579 | 90 | 4.31 | 4.33 | 4.38 | 4.31 | 4.35 | 4.33 | 4.28 | 4.29 | 4.32 | Compounding | Best Practices |

Premier, Inc.
Home-Study CE Evaluations Report - Pharmacists
2024

| Date and Working Program Title | Speaker Name, e-mail address | Credit Hrs | Total # of Registrants | Total # of CE Recipients | # of Pharmacists Receiving CE | Objectives were met | Activity met educational needs | Quality of faculty was satisfactory | Educational materials were useful | Teaching methods were effective | Learning assessment activities were appropriate | Activity did not promote particular product or company | Overall Activity Rating | Specialty Areas | Focus Areas (Outcomes, Safety, Best Practices) |
|---|--|------------|------------------------|--------------------------|-------------------------------|---------------------|--------------------------------|-------------------------------------|-----------------------------------|---------------------------------|---|--|-------------------------|--------------------------|--|
| 2021 Homestudy CE: A Diverse Healthcare Workforce for America's Present and Future | Regina McClinton, PhD; reginamclinton@icloud.com | 1.0 | 143 | 84 | 49 | 4.52 | 4.5 | 4.54 | 4.45 | 4.48 | 4.5 | 4.54 | 4.50 | Pharmacy Administration | Best Practices |
| 2021 Homestudy CE: Achieving and Sustaining USP <800> Compliance | Lilit Smith, PharmD, MBS, BCSCP; lilit@baptisthealth.net | 1.0 | 124 | 81 | 46 | 4.53 | 4.55 | 4.53 | 4.49 | 4.5 | 4.51 | 4.59 | 4.53 | Patient Safety | Safety |
| 2021 Homestudy CE: COVID-19 Management and Therapeutics – What Lessons Did We Learn? | Debra Goff, PharmD, FIDSA, FCCP; debbie.goff@osumc.edu | 1.0 | 147 | 132 | 65 | 4.53 | 4.52 | 4.5 | 4.52 | 4.51 | 4.52 | 4.53 | 4.52 | Disease State Management | Best Practices |
| 2021 Homestudy CE: Creating a Safe Medication Environment in the Emergency Department | Nicole Acquisto, PharmD, FCCP, BCCCP; Nicole_Acquisto@URMC.Rochester.edu | 1.0 | 486 | 367 | 251 | 4.61 | 4.61 | 4.51 | 4.6 | 4.6 | 4.61 | 4.62 | 4.59 | Patient Safety | Safety |
| 2021 Homestudy CE: Integrating Biosimilars into Health Systems | Scott Soefje, PharmD, MBA, BCOP, FCCP, FHOPA; Soefje.Scott@mayo.edu | 1.0 | 243 | 136 | 100 | 4.62 | 4.6 | 4.61 | 4.61 | 4.6 | 4.61 | 4.61 | 4.61 | Disease State Management | Best Practices |
| 2021 Homestudy CE: Laboratory Implementation of CLSI Updates: Recipe for Success | Wendy Szymczak, PhD, D(ABMM), MT(ASCP); wszymcza@montefiore.org | 1.0 | 40 | 21 | 12 | 4.55 | 4.54 | 4.54 | 4.54 | 4.54 | 4.54 | 4.2 | 4.49 | Pharmacy Administration | Best Practices |
| 2021 Homestudy CE: Opioid Stewardship | Jennifer Halsey, MS, PharmD, MHA, BCPS; jhalsey@peacehealth.org | 1.0 | 171 | 137 | 98 | 4.57 | 4.57 | 4.57 | 4.54 | 4.53 | 4.54 | 4.56 | 4.56 | Pain Management | Best Practices |
| | 4.57 | | | | | | | | | | | | | | |
| 2021 Homestudy CE: Pharmacy Residency Preceptor Training: Teaching and Research Skills | Ashley Woodruff, PharmD, BCPS; aew7@buffalo.edu | 1.0 | 234 | 154 | 125 | 4.52 | 4.46 | 4.52 | 4.48 | 4.46 | 4.45 | 4.52 | 4.49 | Pharmacy Administration | Best Practices |
| | 4.51 | | | | | | | | | | | | | | |
| 2021 Homestudy CE: Vancomycin AUC Implementation and Outcomes | Emily L. Heil, PharmD, MS, BCIDP, BCPS, AAHIVP; eheil@rx.umaryland.edu | 1.0 | 116 | 58 | 38 | 4.55 | 4.52 | 4.53 | 4.46 | 4.5 | 4.44 | 4.57 | 4.52 | Patient Safety | Safety |
| | Erin K. McCreary, PharmD, BCPS, BCIDP; mcrearye3@upmc.edu | | | | | | | 4.55 | | | | | | | |
| | Victor Chen, PharmD, BCPS, BCIDP; vic002@health.ucsd.edu | | | | | | | 4.54 | | | | | | | |
| 2022 Homestudy CE: Addressing Pharmacy White-bagging at the State Level: How Providers can Engage to Impact Change | Ken Komorny, PharmD, BCPS; kenneth.komorny@moffitt.org | 1.0 | 193 | 161 | 64 | 4.64 | 4.64 | 4.68 | 4.66 | 4.64 | 4.66 | 4.68 | 4.66 | Pharmacy Law | Best Practices |
| 2022 Homestudy CE: At Your Disposal: Safe and Compliant Pharmaceutical Waste | Bryan C. McCarthy, Jr., PharmD, MS, MJ, FASHP; BMCCarthy@Lifespan.org | 1.0 | 207 | 175 | 80 | 4.58 | 4.54 | 4.56 | 4.56 | 4.56 | 4.57 | 4.61 | 4.57 | Pharmacy Law | Best Practices |
| 2022 Homestudy CE: Best Practices for Controlled Substance Diversion Prevention | Amisha Arya, PharmD, BCSCP; amisha.arya@nyulangone.org | 1.0 | 177 | 143 | 71 | 4.57 | 4.55 | 4.57 | 4.54 | 4.54 | 4.55 | 4.60 | 4.56 | Pharmacy Administration | Best Practices |
| 2022 Homestudy CE: Best Practices Utilizing Diabetes Technology Through Transitions of Care | Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES, FADCES, FCCP; dianamisaacs@gmail.com | 1.0 | 126 | 90 | 44 | 4.59 | 4.59 | 4.62 | 4.57 | 4.57 | 4.57 | 4.61 | 4.59 | Disease State Management | Best Practices |
| 2022 Homestudy CE: CMS Conditions of Participation: Integration into Accreditation Standards | Patricia C. Kienle, RPh, MPA, BCSCP, FASHP; Patricia.Kienle@cardinalhealth.com | 1.0 | 98 | 69 | 35 | 4.66 | 4.63 | 4.61 | 4.63 | 4.63 | 4.61 | 4.64 | 4.63 | Pharmacy Law | Best Practices |
| 2022 Homestudy CE: Establishment and Impact of Clinical Pharmacy Services in an Accountable Care Organization in a Health System | Genevieve Kumapley, PharmD, BCOP; gkumapley@holyname.org | 1.0 | 78 | 71 | 28 | 4.63 | 4.61 | 4.65 | 4.63 | 4.61 | 4.61 | 4.61 | 4.62 | Pharmacy Administration | Best Practices |
| 2022 Homestudy CE: Implementation of a system-wide remote patient monitoring program: increasing access with success | Cathleen Mathew, PharmD, CDE, AE-C; cathleen.mathew@mountsinai.org | 1.0 | 94 | 58 | 27 | 4.57 | 4.55 | 4.62 | 4.59 | 4.59 | 4.55 | 4.57 | 4.59 | Pharmacy Administration | Best Practices |
| | 4.64 | | | | | | | | | | | | | | |
| 2022 Homestudy CE: Improving Nephrotoxin Stewardship by Utilization of Clinical Surveillance | Sandra Kane-Gill, PharmD, MSc, FCCM, FCCP; kane-gill@pitt.edu | 1.0 | 135 | 77 | 42 | 4.6 | 4.58 | 4.58 | 4.57 | 4.54 | 4.57 | 4.64 | 4.58 | Patient Safety | Safety |
| 2022 Homestudy CE: Managing Acute Pain in Opioid Use Disorder | Lee Kral, PharmD, BCPS, CPE; lee-kral@uiowa.edu | 1.0 | 164 | 91 | 60 | 4.63 | 4.63 | 4.64 | 4.65 | 4.64 | 4.64 | 4.66 | 4.64 | Pain Management | Best Practices |
| 2022 Homestudy CE: Medication Safety and Regulatory Compliance in Ambulatory Surgery Centers | Victor Alves, PharmD, BCGP, FASCP; mailto:valves@octariusrx.com | 1.0 | 167 | 143 | 68 | 4.56 | 4.54 | 4.54 | 4.51 | 4.53 | 4.53 | 4.55 | 4.54 | Patient Safety | Safety |
| 2022 Homestudy CE: Pharmacy Law and Ethics | Keith Yoshizuka, PharmD, MBA, JD, FCSHP; kyoshizu@touro.edu | 1.0 | 146 | 97 | 51 | 4.63 | 4.62 | 4.66 | 4.61 | 4.63 | 4.64 | 4.66 | 4.64 | Pharmacy Law | Best Practices |

Premier, Inc.
Home-Study CE Evaluations Report - Pharmacists
2024

| Date and Working Program Title | Speaker Name, e-mail address | Credit Hrs | Total # of Registrants | Total # of CE Recipients | # of Pharmacists Receiving CE | Objectives were met | Activity met educational needs | Quality of faculty was satisfactory | Educational materials were useful | Teaching methods were effective | Learning assessment activities were appropriate | Activity did not promote particular product or company | Overall Activity Rating | Specialty Areas | Focus Areas (Outcomes, Safety, Best Practices) |
|--|--|------------|------------------------|--------------------------|-------------------------------|---------------------|--------------------------------|-------------------------------------|-----------------------------------|---------------------------------|---|--|-------------------------|--------------------------|--|
| 2022 Homestudy CE: Strategies to Enhance and Expand Your Antimicrobial Stewardship Program | Yi Guo, PharmD, BCIDP, yiguo@montefiore.org | 1.0 | 118 | 92 | 36 | 4.66 | 4.66 | 4.58 | 4.64 | 4.63 | 4.64 | 4.65 | 4.64 | Pharmacy Administration | Best Practices |
| 2022 Homestudy CE: Successful Management of Formulary Decisions – Controlling Costs Without Compromising Outcomes | Pavel Goriacko, PharmD, MPH, BCPS; pgoriack@montefiore.org | 1.0 | 92 | 82 | 36 | 4.57 | 4.56 | 4.57 | 4.57 | 4.57 | 4.57 | 4.57 | 4.57 | Pharmacy Administration | Best Practices |
| | Janelle Duran, PharmD, BCPS; janelle.duran@commonspirit.org | | | | | | | 4.55 | | | | | | | |
| 2022 Homestudy CE: The Use of SGLT2 Inhibitors for Heart Failure Management | Judy Cheng, PharmD, MPH, FCCP, BCPS, RPh; judy.cheng@mcphs.edu | 1.0 | 115 | 97 | 62 | 4.63 | 4.63 | 4.63 | 4.62 | 4.63 | 4.64 | 4.63 | 4.63 | Disease State Management | Best Practices |
| 2023 Home-Study CE: 2023 Accreditation Update | Patricia C. Kienle, RPh, MPA, FASHP | 1.0 | 162 | 91 | 60 | 4.54 | 4.54 | 4.55 | 4.5 | 4.5 | 4.49 | 4.56 | 4.53 | Pharmacy Law | Best Practices |
| 2023 Home-Study CE: 2023-2024 Influenza Virus and Vaccine Update | Premier Staff | 1.0 | 119 | 81 | 44 | 4.67 | 4.67 | 4.68 | 4.65 | 4.64 | 4.67 | 4.67 | 4.66 | Immunizations | Best Practices |
| 2023 Home-Study CE: A Joint Commission Primer: It's No Pain at All, When You Follow the Standards | Genevieve Kumapley, PharmD, BCOP | 1.0 | 117 | 96 | 55 | 4.54 | 4.53 | 4.54 | 4.53 | 4.53 | 4.54 | 4.59 | 4.54 | Pain Management | Best Practices |
| 2023 Home-Study CE: DSCSA and the Standards to Support It | Tracy Nasarenko, BS Accounting, MBA | 1.0 | 200 | 106 | 65 | 4.51 | 4.47 | 4.54 | 4.46 | 4.47 | 4.5 | 4.53 | 4.50 | Pharmacy Law | Best Practices |
| 2023 Home-Study CE: Managing Drug Shortages with a Medication Safety Perspective | Kathy Ghomeshi, PharmD, MBA, BCPS, CPPS | 1.0 | 232 | 195 | 112 | 4.59 | 4.58 | 4.59 | 4.6 | 4.59 | 4.59 | 4.6 | 4.59 | Patient Safety | Safety |
| 2023 Homestudy CE: Optimizing Use of Novel Agents to Treat Multidrug-resistant Gram-negative Infections | Ryan K. Shields, PharmD, MS | 1.0 | 151 | 99 | 69 | 4.66 | 4.67 | 4.7 | 4.66 | 4.67 | 4.67 | 4.63 | 4.67 | Disease State Management | Best Practices |
| 2023 Home-Study CE: Perioperative Antimicrobial Stewardship and Pharmacy's Role | Sara Jordan Hyland, PharmD, BCCCP | 1.0 | 278 | 118 | 81 | 4.67 | 4.66 | 4.66 | 4.65 | 4.66 | 4.66 | 4.71 | 4.67 | Disease State Management | Best Practices |
| 2023 Home-Study CE: Thrombolytics for Acute Ischemic Stroke: Have We Found the Right (Tenecte)Plase in Therapy? | Karen Berger, PharmD, FCCM, BCPS, BCCCP | 1.0 | 380 | 269 | 206 | 4.65 | 4.63 | 4.64 | 4.63 | 4.61 | 4.62 | 4.63 | 4.63 | Disease State Management | Best Practices |
| 2023 Home-Study CE: Updates in HIV Treatment and Prevention (HIV/AIDS) | Melanie Berry, PharmD, BCACP | 1.0 | 193 | 128 | 61 | 4.63 | 4.61 | 4.62 | 4.59 | 4.59 | 4.62 | 4.63 | 4.61 | AIDS Therapy | Best Practices |
| 2024 Home-Study CE: Reversal of Direct Factor-Xa Inhibitors, An Evidence Update | Michael P. Gulseth, Pharm. D., BCPS, FMSHP, FASHP; michael.gulseth@sanfordhealth.org | 1.0 | 300 | 161 | 139 | 4.63 | 4.61 | 4.64 | 4.62 | 4.6 | 4.64 | 4.66 | 4.63 | Disease State Management | Best Practices |
| 2024 Home-Study CE: 2024-2025 Influenza Virus and Vaccine Update | Premier Staff | 1.0 | 143 | 86 | 71 | 4.69 | 4.7 | 4.65 | 4.71 | 4.67 | 4.66 | 4.7 | 4.68 | Immunizations | Best Practices |

Premier, Inc.
Home-Study CE Evaluations Report - Pharmacy Technicians
2024

| Date and Working Program Title | Speaker Name, e-mail address | Credit Hrs | Total # of Registrants | Total # of CE Recipients | # of Pharmacy Technicians Receiving CE | Objectives were met | Activity met educational needs | Quality of faculty was satisfactory | Educational materials were useful | Teaching methods were effective | Learning assessment activities were appropriate | Activity did not promote particular product or company | Overall Activity Rating | Specialty Areas | Focus Areas (Outcomes, Safety, Best Practices) |
|---|---|------------|------------------------|--------------------------|--|---------------------|--------------------------------|-------------------------------------|-----------------------------------|---------------------------------|---|--|-------------------------|--------------------------|--|
| 2021 Homestudy CE: A Diverse Healthcare Workforce for America's Present and Future | Regina McClinton, PhD, reginamclinton@jcloud.com | 1.0 | 143 | 84 | 35 | 4.32 | 4.32 | 4.29 | 4.29 | 4.29 | 4.29 | 4.26 | 4.29 | Pharmacy Administration | Best Practices |
| 2021 Homestudy CE: Achieving and Sustaining USP <800> Compliance | Lilit Smith, PharmD, MBS, BCSCP; lilit@baptisthealth.net | 1.0 | 124 | 81 | 35 | 4.41 | 4.4 | 4.41 | 4.35 | 4.31 | 4.3 | 4.38 | 4.37 | Patient Safety | Safety |
| 2021 Homestudy CE: COVID-19 Management and Therapeutics – What Lessons Did We Learn? | Debra Goff, PharmD, FIDSA, FCCP; debbie.goff@osumc.edu | 1.0 | 147 | 132 | 67 | 4.39 | 4.37 | 4.37 | 4.35 | 4.34 | 4.36 | 4.35 | 4.36 | Disease State Management | Best Practices |
| 2021 Homestudy CE: Creating a Safe Medication Environment in the Emergency Department | Nicole Acquisto, PharmD, FCCP, BCCCP; Nicole_Acquisto@URMC.Rochester.edu | 1.0 | 486 | 367 | 116 | 4.44 | 4.41 | 4.41 | 4.45 | 4.45 | 4.47 | 4.47 | 4.44 | Patient Safety | Safety |
| 2021 Homestudy CE: Integrating Biosimilars into Health Systems | Scott Soefje, PharmD, MBA, BCOP, FCCP, FHOPA; Soefje.Scott@mayo.edu | 1.0 | 243 | 136 | 36 | 4.57 | 4.51 | 4.51 | 4.54 | 4.51 | 4.49 | 4.49 | 4.52 | Disease State Management | Best Practices |
| 2021 Homestudy CE: Laboratory Implementation of CLSI Updates: Recipe for Success | Wendy Szymczak, PhD, D(ABMM), MT(ASCP); wszymcza@montefiore.org | 1.0 | 40 | 21 | 9 | 4.39 | 4.36 | 4.39 | 4.36 | 4.43 | 4.32 | 4.39 | 4.38 | Pharmacy Administration | Best Practices |
| 2021 Homestudy CE: Opioid Stewardship | Jennifer Halsey, MS, PharmD, MHA, BCPS; jhalsey@peacehealth.org | 1.0 | 171 | 137 | 39 | 4.33 | 4.3 | 4.29 | 4.33 | 4.34 | 4.27 | 4.24 | 4.30 | Pain Management | Best Practices |
| | 4.31 | | | | | | | | | | | | | | |
| 2021 Homestudy CE: Pharmacy Residency Preceptor Training: Teaching and Research Skills | Erin Slazak, PharmD, BCPS, BCACP; emsabria@buffalo.edu | 1.0 | 234 | 154 | 29 | 4.53 | 4.53 | 4.53 | 4.57 | 4.57 | 4.57 | 4.57 | 4.56 | Pharmacy Administration | Best Practices |
| | 4.57 | | | | | | | | | | | | | | |
| 2021 Homestudy CE: Vancomycin AUC Implementation and Outcomes | Emily L. Heil, PharmD, MS, BCIDP, BCPS, AAHIVP; eheil@rx.umaryland.edu | 1.0 | 116 | 58 | 20 | 4.42 | 4.34 | 4.39 | 4.42 | 4.42 | 4.32 | 4.42 | 4.40 | Patient Safety | Safety |
| | Erin K. McCreary, PharmD, BCPS, BCIDP; mcrearye3@upmc.edu | | | | | | | 4.45 | | | | | | | |
| | Victor Chen, PharmD, BCPS, BCIDP; vic002@health.ucsd.edu | | | | | | | 4.42 | | | | | | | |
| 2022 Homestudy CE: Addressing Pharmacy White-bagging at the State Level: How Providers can Engage to Impact Change | Ken Komorny, PharmD, BCPS; kenneth.komorny@moffitt.org | 1.0 | 193 | 161 | 97 | 4.32 | 4.34 | 4.34 | 4.31 | 4.30 | 4.33 | 4.32 | 4.32 | Pharmacy Law | Best Practices |
| 2022 Homestudy CE: At Your Disposal: Safe and Compliant Pharmaceutical Waste | Bryan C. McCarthy, Jr., PharmD, MS, MJ, FASHP; BMCarthy@Lifespan.org | 1.0 | 207 | 175 | 95 | 4.43 | 4.41 | 4.42 | 4.37 | 4.37 | 4.39 | 4.41 | 4.40 | Pharmacy Law | Best Practices |
| 2022 Homestudy CE: Best Practices for Controlled Substance Diversion Prevention | Amisha Arya, PharmD, BCSCP; amisha.arya@nyulangone.org | 1.0 | 177 | 143 | 72 | 4.39 | 4.37 | 4.39 | 4.35 | 4.39 | 4.39 | 4.36 | 4.38 | Pharmacy Administration | Best Practices |
| 2022 Homestudy CE: Best Practices Utilizing Diabetes Technology Through Transitions of Care | Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES, FADCES, FCCP; dianamisacs@gmail.com | 1.0 | 126 | 90 | 46 | 4.44 | 4.46 | 4.46 | 4.48 | 4.46 | 4.44 | 4.46 | 4.46 | Disease State Management | Best Practices |
| 2022 Homestudy CE: CMS Conditions of Participation: Integration into Accreditation Standards | Patricia C. Kienle, RPH, MPA, BCSCP, FASHP; Patricia.Kienle@cardinalhealth.com | 1.0 | 98 | 69 | 34 | 4.50 | 4.49 | 4.54 | 4.51 | 4.47 | 4.50 | 4.49 | 4.50 | Pharmacy Law | Best Practices |
| 2022 Homestudy CE: Establishment and Impact of Clinical Pharmacy Services in an Accountable Care Organization in a Health System | Genevieve Kumapley, PharmD, BCOP; gkumapley@holyname.org | 1.0 | 78 | 71 | 43 | 4.53 | 4.47 | 4.49 | 4.50 | 4.47 | 4.47 | 4.53 | 4.49 | Pharmacy Administration | Best Practices |
| 2022 Homestudy CE: Implementation of a system-wide remote patient monitoring program: increasing access with success | Cathleen Mathew, PharmD, CDE, AE-C; cathleen.mathew@mountsinai.org | 1.0 | 94 | 58 | 31 | 4.55 | 4.57 | 4.55 | 4.55 | 4.53 | 4.57 | 4.53 | 4.55 | Pharmacy Administration | Best Practices |
| | Ruchi Tiwari, PharmD, MS; ruchi.tiwari@mountsinai.org | | | | | | | 4.57 | | | | | | | |
| 2022 Homestudy CE: Improving Nephrotoxin Stewardship by Utilization of Clinical Surveillance | Sandra Kane-Gill, PharmD, MSc, FCCM, FCCP; kane-gill@pitt.edu | 1.0 | 135 | 77 | 35 | 4.47 | 4.43 | 4.43 | 4.47 | 4.45 | 4.45 | 4.45 | 4.45 | Patient Safety | Safety |
| 2022 Homestudy CE: Managing Acute Pain in Opioid Use Disorder | Lee Kral, PharmD, BCPS, CPE; lee-kral@uiowa.edu | 1.0 | 164 | 91 | 31 | 4.65 | 4.65 | 4.70 | 4.65 | 4.67 | 4.65 | 4.67 | 4.66 | Pain Management | Best Practices |
| 2022 Homestudy CE: Medication Safety and Regulatory Compliance in Ambulatory Surgery Centers | Victor Alves, PharmD, BCGP, FASCP; mailto.valves@octariusrx.com | 1.0 | 167 | 143 | 75 | 4.43 | 4.45 | 4.45 | 4.43 | 4.43 | 4.45 | 4.41 | 4.44 | Patient Safety | Safety |

Premier, Inc.
Home-Study CE Evaluations Report - Pharmacy Technicians
2024

| Date and Working Program Title | Speaker Name, e-mail address | Credit Hrs | Total # of Registrants | Total # of CE Recipients | # of Pharmacy Technicians Receiving CE | Objectives were met | Activity met educational needs | Quality of faculty was satisfactory | Educational materials were useful | Teaching methods were effective | Learning assessment activities were appropriate | Activity did not promote particular product or company | Overall Activity Rating | Specialty Areas | Focus Areas (Outcomes, Safety, Best Practices) |
|--|--|------------|------------------------|--------------------------|--|---------------------|--------------------------------|-------------------------------------|-----------------------------------|---------------------------------|---|--|-------------------------|--------------------------|--|
| 2022 Homestudy CE: Pharmacy Law and Ethics | Keith Yoshizuka, PharmD, MBA, JD, FCSHP; kyoshizu@touro.edu | 1.0 | 146 | 97 | 46 | 4.48 | 4.49 | 4.46 | 4.45 | 4.46 | 4.48 | 4.45 | 4.47 | Pharmacy Law | Best Practices |
| 2022 Homestudy CE: Strategies to Enhance and Expand Your Antimicrobial Stewardship Program | Yi Guo, PharmD, BCIDP, yiguo@montefiore.org | 1.0 | 118 | 92 | 56 | 4.70 | 4.60 | 4.60 | 4.70 | 4.70 | 4.70 | 4.70 | 4.67 | Pharmacy Administration | Best Practices |
| 2022 Homestudy CE: Successful Management of Formulary Decisions – Controlling Costs Without Compromising Outcomes | Pavel Goriacko, PharmD, MPH, BCPS; pgoriack@montefiore.org | 1.0 | 92 | 82 | 46 | 4.59 | 4.54 | 4.56 | 4.56 | 4.57 | 4.57 | 4.57 | 4.57 | Pharmacy Administration | Best Practices |
| | Janelle Duran, PharmD, BCPS; janelle.duran@commonspirit.org | | | | | | | 4.56 | | | | | | | |
| 2022 Homestudy CE: The Use of SGLT2 Inhibitors for Heart Failure Management | Judy Cheng, PharmD, MPH, FCCP, BCPS, RPh; judy.cheng@mcphs.edu | 1.0 | 115 | 97 | 35 | 4.37 | 4.33 | 4.39 | 4.38 | 4.38 | 4.38 | 4.38 | 4.37 | Disease State Management | Best Practices |
| 2023 Home-Study CE: 2023 Accreditation Update | Patricia C. Kienle, RPh, MPA, FASHP; Patricia.Kienle@cardinalhealth.com | 1.0 | 162 | 91 | 31 | 4.46 | 4.46 | 4.46 | 4.43 | 4.41 | 4.41 | 4.5 | 4.45 | Pharmacy Law | Best Practices |
| 2023 Home-Study CE: 2023-2024 Influenza Virus and Vaccine Update | Premier Staff | 1.0 | 119 | 81 | 37 | 4.64 | 4.58 | 4.56 | 4.56 | 4.56 | 4.53 | 4.47 | 4.57 | Immunizations | Best Practices |
| 2023 Home-Study CE: A Joint Commission Primer: It's No Pain at All, When You Follow the Standards | Genevieve Kumapley, PharmD, BCOP; gkumapley@ | 1.0 | 117 | 96 | 41 | 4.38 | 4.37 | 4.38 | 4.4 | 4.38 | 4.37 | 4.4 | 4.38 | Pain Management | Best Practices |
| 2023 Home-Study CE: DSCSA and the Standards to Support It | Tracy Nasarenko, BS Accounting, MBA; TNasarenko@gs1us.org | 1.0 | 200 | 106 | 41 | 4.35 | 4.3 | 4.46 | 4.39 | 4.35 | 4.33 | 4.5 | 4.38 | Pharmacy Law | Best Practices |
| 2023 Home-Study CE: Managing Drug Shortages with a Medication Safety Perspective | Kathy Ghomeshi, PharmD, MBA, BCPS, CPPS; kg-rx@ghomeshi.com | 1.0 | 232 | 195 | 83 | 4.49 | 4.48 | 4.5 | 4.47 | 4.45 | 4.46 | 4.5 | 4.48 | Patient Safety | Safety |
| 2023 Homestudy CE: Optimizing Use of Novel Agents to Treat Multidrug-resistant Gram-negative Infections | Ryan K. Shields, PharmD, MS; shieldsrk@upmc.edu | 1.0 | 151 | 99 | 30 | 4.44 | 4.51 | 4.49 | 4.51 | 4.49 | 4.49 | 4.51 | 4.49 | Disease State Management | Best Practices |
| 2023 Home-Study CE: Perioperative Antimicrobial Stewardship and Pharmacy's Role | Sara Jordan Hyland, PharmD, BCCCP; Sara.Jordan@ohiohealth.com | 1.0 | 278 | 118 | 37 | 4.23 | 4.18 | 4.22 | 4.14 | 4.09 | 4.09 | 4.28 | 4.18 | Disease State Management | Best Practices |
| 2023 Home-Study CE: Thrombolytics for Acute Ischemic Stroke: Have We Found the Right (Tenecte)Plase in Therapy? | Karen Berger, PharmD, FCCM, BCPS, BCCCP; karenberger7@gmail.com | 1.0 | 380 | 269 | 63 | 4.47 | 4.39 | 4.46 | 4.48 | 4.45 | 4.44 | 4.45 | 4.45 | Disease State Management | Best Practices |
| 2023 Home-Study CE: Updates in HIV Treatment and Prevention (HIV/AIDS) | Melanie Berry, PharmD, BCACP; mberry2@bidmc.harvard.edu | 1.0 | 193 | 128 | 67 | 4.37 | 4.38 | 4.4 | 4.37 | 4.37 | 4.37 | 4.38 | 4.38 | AIDS Therapy | Best Practices |
| 2024 Home-Study CE: Reversal of Direct Factor-Xa Inhibitors, An Evidence Update | Michael P. Gulseth, Pharm. D., BCPS, FMSHP, FASHP; michael.gulseth@sanfordhealth.org | 1.0 | 300 | 161 | 22 | 4.52 | 4.44 | 4.44 | 4.4 | 4.48 | 4.48 | 4.48 | 4.46 | Disease State Management | Best Practices |
| 2024 Home-Study CE: 2024-2025 Influenza Virus and Vaccine Update | Premier Staff | 1.0 | 143 | 86 | 15 | 4.56 | 4.59 | 4.59 | 4.59 | 4.59 | 4.59 | 4.59 | 4.59 | Immunizations | Best Practices |

Premier, Inc.
Breakthroughs CE Evaluations Report
2024

Pharmacists Only

| Date and Activity Topic | Speaker(s) | Credit Hrs | Total # of Registrants | Total # of Participants receiving CE credit | Objectives were met | Activity met educational needs | Quality of faculty was satisfactory | Educational materials were useful | Teaching methods were effective | Learning assessment activities were appropriate | Activity did not promote product or company | Overall Activity Rating | Specialty Areas | Focus Areas (Outcomes, Safety, Best Practices) |
|---|--|------------|------------------------|---|---------------------|--------------------------------|-------------------------------------|-----------------------------------|---------------------------------|---|---|-------------------------|-------------------------|--|
| July 24, 2024: Pharm-1: Advancements in Drug Distribution: Blockchain Networking and Centralized Service Model | Brandon McLain; Brandon.McLain@bhshi.com | 1.0 | 22 | 22 | 4.68 | 4.64 | 4.68 | 4.55 | 4.68 | 4.59 | 4.68 | 4.65 | Pharmacy Administration | Best Practices |
| | Thomas Matanich, MBA, PMP; Thomas.Matanich@bhshi.com | | | | | | 4.68 | | | | | | | |
| July 24, 2024: Pharm-2: Reducing Pharmacy Costs Through Management of Drug Shortages and IV Waste | David Cecere, PharmD, MBA; cecered@wvumedicine.org | 1.0 | 22 | 21 | 4.67 | 4.67 | 4.67 | 4.67 | 4.67 | 4.67 | 4.67 | 4.67 | Pharmacy Administration | Best Practices |
| | Marc Phillips, PharmD, CPHQ, 340B ACE; marc.phillips1@wvumedicine.org | | | | | | 4.67 | | | | | | | |
| July 24, 2024: Pharm-6: Optimizing Pharmaceutical Distribution Management: Strategies for Price Transparency and Wholesaler Relations | Mohammed Abdulwahhab; madbulwahhab@mhs.net | 1.0 | 26 | 23 | 4.65 | 4.61 | 4.70 | 4.61 | 4.70 | 4.52 | 4.65 | 4.63 | Pharmacy Administration | Best Practices |
| | Kyle Brauer; Kyle.Brauer@baycare.org | | | | | | - | | | | | | | |
| July 25, 2024: LO-2: Work Force Optimization: Strategies and Solutions for Retention Success with Pharmacy Talent | Michael Nnandi; michael.nnadi@harrishealth.org | 1.0 | 1 | 1 | 5.00 | 5.00 | 5.00 | 5.00 | 5.00 | 5.00 | 5.00 | 5.00 | Pharmacy Administration | Best Practices |
| July 25, 2024: Pharm-3: Managing Drug Diversion | Austin Kucher; Austin.kucher@adventhealth.com | 1.0 | 25 | 24 | 4.67 | 4.71 | 4.71 | 4.67 | 4.67 | 4.67 | 4.67 | 4.69 | Pharmacy Administration | Best Practices |
| | Karen Hancock; Karen_Hancock@bhshi.org | | | | | | 4.71 | | | | | | | |
| July 25, 2024: Pharm-4: My 340BESP Experience | Michael K. Lessard, RPh, MBA, 340B ACE; MLessard@peacehealth.org | 1.0 | 9 | 9 | 4.67 | 4.67 | 4.78 | 4.67 | 4.67 | 4.67 | 4.67 | 4.69 | Pharmacy Law | Best Practices |
| July 25, 2024: Pharm-5: Optimization of Biosimilar Intake and Patient Access Considerations – Harris Health System Experience | Jessica Njoku, PharmD, MPH, BCPS; jessica.njoku@harrishealth.org | 1.0 | 11 | 8 | 4.78 | 4.67 | 4.56 | 4.67 | 4.33 | 4.33 | 4.89 | 4.60 | Pharmacy Administration | Best Practices |

Premier, Inc.
Pharmacy Executive Conference, Capstone, Yankee Alliance and Premier Member Meeting CE Evaluations Reports
2024

Pharmacy Executive Conference CEs

| Date and Program Title | Speaker Name, e-mail address | Credit Hrs | Total # of Registrants | Total # of CE Recipients | # of Pharmacy Technicians Receiving CE | Objectives were met | Activity met educational needs | Quality of faculty was satisfactory | Educational materials were useful | Teaching methods were effective | Learning assessment activities were appropriate | Actively participated in activity | Activity did not promote product or company | Overall Activity Rating | Specialty Areas | Focus Areas (Outcomes, Safety, Best Practices) |
|---|---|------------|------------------------|--------------------------|--|---------------------|--------------------------------|-------------------------------------|-----------------------------------|---------------------------------|---|-----------------------------------|---|-------------------------|--------------------------|--|
| March 20, 2024: Integrating a Population Health Clinical Pharmacy Program for Management of Early Stage Diabetic Kidney Disease (DKD) at a Metropolitan Health System | Jacqueline Mullakary, PharmD, BCACP, CDCES, AE-C; Jacqueline.Mullakary@mountsinai.org | .5 | 6 | 6 | - | 5.0 | 5.0 | 5.0 | 5.0 | 5.0 | 5.0 | 5.0 | 5.0 | 5.00 | Disease State Management | Best Practices |
| | Catherine Liu, PharmD, BCPS, BCGP; Catherine.Liu@mountsinai.org | | | | | | | 5.0 | | | | | | | | |
| March 20, 2024: The Evolving Nature of Formulary Management – Dealing with High Cost Medications | Fernando Rodriguez, PharmD; fernando_rodriguez@premierinc.com | 1.0 | 6 | 6 | - | 5.0 | 5.0 | 5.0 | 5.0 | 5.0 | 5.0 | 5.0 | 5.0 | 5.00 | Pharmacy Administration | Best Practices |

Capstone CEs

| Date and Working Program Title | Speaker Name, e-mail address | Credit Hrs | Total # of Registrants | Total # of CE Recipients | # of Pharmacists Receiving CE | Objectives were met | Activity met educational needs | Quality of faculty was satisfactory | Educational materials were useful | Teaching methods were effective | Learning assessment activities were appropriate | Actively participated in activity | Activity did not promote product or company | Overall Activity Rating | Specialty Areas | Focus Areas (Outcomes, Safety, Best Practices) |
|---|--|------------|------------------------|--------------------------|-------------------------------|---------------------|--------------------------------|-------------------------------------|-----------------------------------|---------------------------------|---|-----------------------------------|---|-------------------------|-------------------------|--|
| October 15, 2024: Standardized Education Impact on Medication History Errors in Specialist Practice | Jeffrey Lewis, PharmD, BCPS, BCACP, CDCES; jLewis2@utmck.edu | 1.0 | 7 | 3 | 3 | 4.67 | 4.67 | 5.00 | 4.67 | 4.67 | 4.67 | 4.67 | 5 | 4.75 | Patient Safety | Safety |
| October 16, 2024: Advancements in Drugs Distribution: Blockchain Networking and Centralized Service Model | Thomas Matanich, MBA, PMP; Thomas.Matanich@bhsi.com | 1.0 | 9 | 4 | 4 | 4.75 | 4.5 | 5.00 | 4.75 | 4.75 | 4.75 | 4.75 | 5.00 | 4.78 | Pharmacy Administration | Best Practices |

Yankee Alliance CEs

Pharmacists

| Date and Activity Topic | Speaker(s) | Credit Hrs | Total # of Registrants | # of Participants Receiving CE credit | # of Pharmacists Receiving CE credit | Objectives were met | Activity met educational needs | Quality of faculty was satisfactory | Educational materials were useful | Teaching methods were effective | Learning assessment activities were appropriate | Actively participated in activity | Did not promote product or company | Overall Activity Rating | Specialty Areas | Focus Areas (Outcomes, Safety, Best Practices) |
|---|---|------------|------------------------|---------------------------------------|--------------------------------------|---------------------|--------------------------------|-------------------------------------|-----------------------------------|---------------------------------|---|-----------------------------------|------------------------------------|-------------------------|-------------------------|--|
| October 22, 2024: An In-Depth Look at Vetting Outsourced Services for IV Admixtures (503B) | Kevin N. Hansen, PharmD, MS, BCSCP; kevin.hansen@premierinc.com | 1.0 | 9 | 7 | 6 | 4.83 | 4.83 | 5 | 4.83 | 4.83 | 5 | 5 | 5 | 4.92 | Compounding | Best Practices |
| October 23, 2024: Advancements in Drugs Distribution: Blockchain Networking and Centralized Service Model | Thomas Matanich, MBA, PMP; Thomas.Matanich@bhsi.com | 1.0 | 9 | 8 | 7 | 4.86 | 4.86 | 4.71 | 4.71 | 4.71 | 4.86 | 4.86 | 4.86 | 4.79 | Pharmacy Administration | Best Practices |

Pharmacy Technicians

| Date and Activity Topic | Speaker(s) | Credit Hrs | Total # of Registrants | # of Participants Receiving CE credit | # of Pharmacy Technicians Receiving CE credit | Objectives were met | Activity met educational needs | Quality of faculty was satisfactory | Educational materials were useful | Teaching methods were effective | Learning assessment activities were appropriate | Actively participated in activity | Did not promote product or company | Overall Activity Rating | Specialty Areas | Focus Areas (Outcomes, Safety, Best Practices) |
|---|---|------------|------------------------|---------------------------------------|---|---------------------|--------------------------------|-------------------------------------|-----------------------------------|---------------------------------|---|-----------------------------------|------------------------------------|-------------------------|-------------------------|--|
| October 22, 2024: An In-Depth Look at Vetting Outsourced Services for IV Admixtures (503B) | Kevin N. Hansen, PharmD, MS, BCSCP; kevin.hansen@premierinc.com | 1.0 | 9 | 7 | 1 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5.00 | Compounding | Best Practices |
| October 23, 2024: Advancements in Drugs Distribution: Blockchain Networking and Centralized Service Model | Thomas Matanich, MBA, PMP; Thomas.Matanich@bhsi.com | 1.0 | 9 | 8 | 1 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5.00 | Pharmacy Administration | Best Practices |

Premier Member Meeting CE

| Date and Program Title | Speaker Name, e-mail address | Credit Hrs | Total # of Registrants | Total # of CE Recipients | # of Pharmacy Technicians Receiving CE | Objectives were met | Activity met educational needs | Quality of faculty was satisfactory | Educational materials were useful | Teaching methods were effective | Learning assessment activities were appropriate | Actively participated in activity | Activity did not promote product or company | Overall Activity Rating | Specialty Areas | Focus Areas (Outcomes, Safety, Best Practices) |
|--|---|------------|------------------------|--------------------------|--|---------------------|--------------------------------|-------------------------------------|-----------------------------------|---------------------------------|---|-----------------------------------|---|-------------------------|-----------------|--|
| December 8, 2024: DSCSA: Implementation Requirements Post FDA Stabilization Period | Carl Gomberg, Lead Solution Analyst, Premier, Inc.; carl_gomberg@premierinc.com | .50 | 21 | 21 | - | 4.67 | 4.67 | 4.67 | 4.67 | 4.62 | 4.57 | 4.67 | 4.67 | 4.65 | Pharmacy Law | Best Practices |

Premier, Inc.
CE Teleconference Comments Report - Pharmacists
2024

| Date and Activity Topic | Speaker(s) | Total # of Registrants | Total # of Participants receiving CE credit | # of Pharmacists receiving CE credit | Bias, promotion or commercial advertisement? | Comments (number of members with same response in parentheses) |
|---|---|------------------------|---|--------------------------------------|---|--|
| January 30, 2024: Adalimumab-SOS: Navigating the Market Entry of Adalimumab Biosimilars in the US | Stefanie Cisek, PharmD, BCACP. stefanie.cisek@nm.org | 590 | 459 | 387 | NA/None (72) | 1. Captive speaker; 2. Clear/Concise (4); 3. Comprehensive; 4. Knowledgeable (9); 5. Good/Very good/Great/Excellent (9); 6. Good/Very good/Great/Excellent presentation (8); 7. Good/Very good/Great/Excellent speaker (7); 8. Great job (2); 9. Enjoyable; 10. Informative (14); 11. Interesting (2); 12. Nice comparison; 13. Nice job; 14. Nice pace; 15. Thank you; 16. Very engaging; 17. Well organized |
| February 20, 2024: Medication Management of Parkinson's disease (PD) and Sequelae | Jacquelyn Bainbridge PharmD, FCCP; jacci.bainbridge@cuanschutz.edu | 662 | 490 | 422 | NA/None (78) | 1. Awesome; 2. Clear/Concise; 3. Comprehensive; 4. Detailed information; 5. Engaging; 6. Good/Very good/Great/Excellent (9); 7. Good/Very good/Great/Excellent job (8); 8. Good pace; 9. Good/Very good/Great/Excellent presentation (16); 10. Good/Very good/Great/Excellent speaker (9); 11. Fantastic; 12. More focus on PD management; 13. Patient case presentations would have been helpful; 14. Helpful; 15. Informative (15); 16. Interesting (3); 17. Knowledgeable (16); 18. Nice job; 19. Passionate; 20. Thank you (3); 21. Thorough (2); 22. Useful information (2); 23. Well done |
| March 20, 2024: What Lies Ahead – A Look at the Biosimilar, Infectious Diseases and Specialty/Oncology Drug Pipeline in 2024-2025 | Liya Davydov, PharmD, BCPS, BCGP; liya_davydov@premierinc.com | 679 | 510 | 428 | NA/None (71) | 1. Covered many medications; 2. Good/Very good/Great/Excellent (10); 3. Good/Very good/Great/Excellent presentation (7); 4. Good/Very good/Great/Excellent speaker (6); 5. Great job (2); 6. Timely topic; presented good ideas; 7. Informative (19); 8. Interesting; 9. Knowledgeable (11); 10. Useful information/materials (2); 11. Nice job; 12. Not enough time (5); 13. Objective delivery; 14. Relevant to my practice; 15. Thank you (2); 16. Thorough (2); 17. Very detailed; 18. Well done; 19. Wow, what a topic! |
| April 24, 2024: Buprenorphine in the Management of Opioid Use Disorder (OUD): Updates on Role in Therapy, Accessibility, and Novel Dosing Strategies | Michael Biglow, PharmD, BCPS, BCPP; mbiglow@phs.org | 682 | 493 | 424 | NA/None (70) | 1. Amazing speaker; 2. Awesome speaker; 3. Clear/Concise (4); 4. Communicated effectively; 5. Difficult topic, but the slides helped somewhat; 6. Easy to follow; 7. Good/Very good/Great/Excellent (12); 8. Good/Very good/Great/Excellent job (4); 9. Good/Very good/Great/Excellent presentation (11); 10. Good/Very good/Great/Excellent speaker (11); 11. Informative (10); 12. Interesting; 13. Knowledgeable (15); 14. Presentation materials were very complete; 15. Professional; 16. Thank you (5); 17. Valuable information (2); 18. Very nice overview; 19. Very non-biased and helpful; 20. Very thorough; 21. Very timely topic |
| May 22, 2024: Cultivating an Inclusive Culture: Managing Difficult Co-Workers Including Yourself | Kevin N. Hansen, PharmD, MS, BCSCP; kevin.hansen@premierinc.com | 675 | 492 | 409 | NA/None (66) | 1. Amazing job; 2. Awesome topic; 3. Clear/Concise (2); 4. Detailed; 5. Easy to follow/understand (2); 6. Effective speaker; 7. Engaging (3); 8. Enjoyed the topic (2); 9. Good/Very good/Great/Excellent (5); 10. Good/Very good/Great/Excellent presentation (13); 11. Good/Very good/Great/Excellent speaker (7); 12. Exceptional speaker; 13. Great job (3); 14. Great tools and examples provided; 15. Informative (16); 16. Insightful; 17. Interesting (6); 18. Intuitive lecture; 19. Knowledgeable (6); 20. Nice job; 21. Valuable information; 22. Very energetic; 23. Very enthusiastic; 24. Very thorough; 25. Very useful strategies; 26. Well organized |
| | Robert P. Granko, PharmD, MBA, FASHP, FNCP; rgranko@pennstatehealth.psu.edu | | | | | 1. Awesome topic; 2. Clear/Concise; 3. Deep analysis; 4. Easy to follow/understand (2); 5. Engaging; 6. Enjoyed the presentation; 7. Enthusiastic (2); 8. Good/Very good/Great/Excellent (3); 9. Good/Very good/Great/Excellent presentation (9); 10. Good/Very good/Great/Excellent speaker (6); 11. Good examples; 12. Great job (4); 13. Great tools and examples provided (2); 14. Informative (16); 15. Insightful; 16. Interesting (4); 17. Knowledgeable (7); 18. Nice job; 19. Passionate; 20. Provocative; 21. Very good delivery; 22. Very thorough; 23. Very valuable content; 24. Well done |
| June 26, 2024: Protecting Our Little Ones! Reducing Medication Errors in Neonates and Pediatrics | Judith Scala, PharmD, BCPPS; JScala@saintpetersuh.com | 886 | 632 | 541 | NA/None (87) | 1. Clear/Concise (7); 2. Comprehensive; 3. Confident; 4. Covered a wide area of topics; 5. Descriptive; 6. Easy to follow; 7. Engaging (3); 8. Good/Very good/Great/Excellent (9); 9. Good/Very good/Great/Excellent examples (6); 10. Good/Very good/Great/Excellent presentation (16); 11. Good/Very good/Great/Excellent job (4); 12. Good/Very good/Great/Excellent speaker (6); 13. Enjoyed the presentation (2); 14. Informative (19); 15. Insightful; 16. Interesting (5); 17. Keep up the good/great work (2); 18. Knowledgeable (16); 19. Many key points made; 20. Organized (7); 21. Provocative; 22. Thank you (2); 23. Thorough (2); 24. Very professional; 25. Well paced; 26. Wonderful (2) |
| July 24, 2024: Updates GLP-1 & GIP Agonists for Weight Loss | Melissa Lipari, PharmD, BCACP; mlipari@wayne.edu | 693 | 518 | 445 | NA/None (85); by the end, definitely supported using therapy but seems to be data driven; a little heavy on the tirzepatide | 1. Awesome; 2. Clear/Concise (4); 3. Comprehensive; 4. confident; 5. Enjoyable; 6. Good/Very good/Great/Excellent (14); 7. Good/Very good/Great/Excellent presentation (17); 8. Good/Very good/Great/Excellent speaker (8); 9. Great hot topic; 10. Good graphics and drug trial breakdown; 11. Good/Very good/Great/Excellent job (7); 12. Informative (18); 13. Interesting (3); 14. Knowledgeable (7); 15. Nice job; 16. Thank you (4); 17. Useful information (2); 18. Very competent; 19. Very helpful (2); 20. Very thorough; 21. Very timely; 22. Well organized |
| | Pranodini Kale-Pradhan, PharmD, FCCP, FIDSA; pkale@wayne.edu | | | | | 1. Enjoyable; 2. Good/Very good/Great/Excellent presentation (2); 3. Good/Very good/Great/Excellent (4); 4. Good graphics and drug trial breakdown; 5. Great hot topic; 6. Great job (3); 7. Great speaker; 8. Informative; 9. Knowledgeable; 10. Thank you; 11. Very competent; 12. Very helpful; 13. Very interesting; 14. Very timely |
| | Alison Lobkovich, PharmD; alison.lobkovich@wayne.edu | | | | | 1. Enjoyable; 2. Good/Very good/Great/Excellent presentation (2); 3. Good/Very good/Great/Excellent (4); 4. Good graphics and drug trial breakdown; 5. Great hot topic; 6. Great job (3); 7. Great speaker; 8. Informative; 9. Knowledgeable; 10. Thank you; 11. Very competent; 12. Very helpful; 13. Very interesting; 14. Very timely |
| August 21, 2024: Optimizing Pharmaceutical Distribution Management: Strategies for Price Transparency and Wholesaler Relations | Mohammed Abdulwahhab; madbulwahhab@mhs.net | 511 | 393 | 325 | NA/None (46) | 1. Clear/Concise (2); 2. Good/Very good/Great/Excellent (7); 3. Good/Very good/Great/Excellent presentation (7); 4. Good/Very good/Great/Excellent speaker (2); 5. Great job (5); 6. Informative (10); 7. Interesting (2); 8. Knowledgeable (2); 9. Nice job; 10. Thorough; 11. Wonderful job |
| | Kyle Brauer; Kyle.Brauer@baycare.org | | | | | 1. Captivating; 2. Engaging (2); 3. Good/Very good/Great/Excellent (2); 4. Great job; 5. Good/Very good/Great/Excellent presentation (2); 6. Good/Very good/Great/Excellent speakers (2); 7. Informative (7); 8. Interesting; 9. Knowledgeable (2); 10. Offered great ideas |
| September 17, 2024: The Future is Now: The Impact of Artificial Intelligence on Medication Use Safety | Steven Smoke, PharmD, BCIDP; Steven.Smoke@rwjrh.org | 772 | 593 | 507 | NA/None (88) | 1. Appreciated the explanations; 2. Clear/Concise; 3. Confident; 4. Engaging (2); 5. Good/Very good/Great/Excellent (11); 6. Good/Very good/Great/Excellent presentation (10); 7. Good/Very good/Great/Excellent speaker (6); 8. Great job (3); 9. Great pace; 10. Great use of examples; 11. Informative (13); 12. Insightful; 13. Interesting (4); 14. Knowledgeable (7); 15. Nice job; 16. OK (2); 17. Relevant information; 18. Slides [were] too busy; 19. Staying ahead of the game; 20. Super; 21. Very mindful |
| | Daniel T. Abazia, PharmD, BCPS, CPPS; dabazia@pharmacy.rutgers.edu | | | | | 1. Good/Very good/Great/Excellent presentation (9); 2. Detailed; 3. Engaging (4); 4. Enjoyable; 5. Enthusiastic; 6. Good/Very good/Great/Excellent (12); 7. Good/Very good/Great/Excellent speaker (8); 8. Good/Very good/Great/Excellent job (6); 9. Great pace and utilization of examples; 10. In tune with integration and future application of AI; 11. Informative (18); 12. Insightful; 13. Interesting (7); 14. Knowledgeable (12); 15. Nice job; 16. OK; 17. They did well; 18. Timely information; 19. Well done; 20. Slides [were] too busy; 21. Staying ahead of the game |
| October 24, 2024: Multiple Sclerosis: Overview and Advances in Treatment | Mitra Habibi, PharmD; mhbab1@uic.edu | 652 | 504 | 416 | NA/None (74) | 1. Clear/Concise; 2. Engaging; 3. Enlightening; 4. Good/Very good/Great/Excellent (10); 5. Good/Very good/Great/Excellent presentation (11); 6. Good/Very good/Great/Excellent speaker (8); 7. Informative (11); 8. Interesting; 9. Knowledgeable (10); 10. OK; 11. Passionate; 12. Slides were too busy and difficult to follow; 13. Thank you/Thanks (3); 14. Thorough (3); 15. Succinct; 16. Too soft spoken; 17. Complex but well covered; 18. Detailed; 19. Well organized |
| November 20, 2024: Leading Analytics Strategy to Support the Enterprise | David Agüero, PharmD, MSTL, FASHP, FAMILA; david.agüero@stjude.org | 660 | 489 | 408 | NA/None (70) | 1. Appreciated the live CE; 2. Clear/Concise (2); 3. Easy to follow; 4. Enjoyed the presentation (2); 5. Entertaining; 6. Good/Very good/Great/Excellent (11); 7. Excellent job; 8. Good/Very good/Great/Excellent presentation (15); 9. Good/Very good/Great/Excellent speaker (8); 10. Good pace; 11. Informative (12); 12. Insightful; 13. Interesting (2); 14. Low audio (2); 15. OK; 16. Thank you (3); 17. Very helpful; 18. Very knowledgeable (3); 19. Well done; 20. Well organized |
| December 18, 2024: A Gene Therapy Primer for Health Systems | Blake Shay, PharmD, MS; Blake.Shay@baycare.org (blakeshay2014@gmail.com) | 591 | 439 | 368 | None | 1. Easy to follow; 2. Good/Very good/Great/Excellent presentation (2); 3. Good speaker; 4. Great topic; 5. Helpful; 6. Informative (4); 7. Offered practical applications; 8. Thank you; 9. Presentation dealt more with procurement, storage and handling; 10. Very knowledgeable; 11. Well organized |

Premier, Inc.
CE Teleconference Comments Report - Pharmacy Technicians
2024

| Date and Activity Topic | Speaker(s) | Total # of Registrants | Total # of Participants receiving CE credit | # of Pharmacy Techs receiving CE credit | Bias, promotion or commercial advertisement? | Comments (number of members with same response in parentheses) |
|---|--|------------------------|---|---|--|---|
| January 30, 2024: Adalimumab-SOS: Navigating the Market Entry of Adalimumab Biosimilars in the US | Stefanie Cisek, PharmD, BCACP; stefanie.cisek@nm.org | 590 | 459 | 72 | NA/None (8) | 1. Informative; 2. Good/Very good/Great/Excellent speaker (3); 3. Excellent job; 4. Knowledgeable; 5. Engaging; 6. Interesting; 7. Very good delivery |
| February 20, 2024: Medication Management of Parkinson's disease (PD) and Sequelae | Jacquelyn Bainbridge PharmD, FCCP; jacci.bainbridge@cuanschutz.edu | 662 | 490 | 68 | NA/None (8) | 1. Well spoken; 2. Great; 3. Clear/Concise; 4. Informative; 5. Good/Very good/Great/Excellent speaker (2); 6. Interesting; 7. Great job; 8. Effective |
| March 20, 2024: What Lies Ahead – A Look at the Biosimilar, Infectious Diseases and Specialty/Oncology Drug Pipeline in 2024-2025 | Liya Davydov, PharmD, BCPS, BCGP; liya_davydov@premierinc.com | 679 | 510 | 82 | NA/None (8) | 1. Good/Very good/Great/Excellent speaker (3); 2. Very informative; 3. Interesting; 4. Clear/Concise; 5. Great job; 6. Precise and thorough |
| April 24, 2024: Buprenorphine in the Management of Opioid Use Disorder (OUD): Updates on Role in Therapy, Accessibility, and Novel Dosing Strategies | Michael Biglow, PharmD, BCPS, BCPP; mbiglow@phs.org | 682 | 493 | 69 | NA/None (7) | 1. Excellent speaker; 2. Great job; 3. Informative; 4. Clear/Concise; 5. Easy to understand; 6. Knowledgeable; 7. Interesting |
| May 22, 2024: Cultivating an Inclusive Culture: Managing Difficult Co-Workers Including Yourself | Kevin N. Hansen, PharmD, MS, BCSCP; kevin.hansen@premierinc.com | 675 | 492 | 83 | NA/None (13) | 1. Knowledgeable (2); 2. Clear/Concise (3); 3. Good/Very good/Great/Excellent (2); 4. Very professional; 5. Excellent speaker; 6. Informative (4); 7. Very straightforward; 8. Interesting |
| | Robert P. Granko, PharmD, MBA, FASHP, FNCAP; rgranko@pennstatehealth.psu.edu | | | | | 1. Knowledgeable; 2. Clear/Concise; 3. Good/Very good/Great/Excellent (2); 4. Very professional; 5. Excellent speaker; 6. Informative (3); 7. Interesting (2); 8. Explained real situations; 9. Great delivery; 10. Straight to the point |
| June 26, 2024: Protecting Our Little Ones! Reducing Medication Errors in Neonates and Pediatrics | Judith Scala, PharmD, BCPPS; JScala@saintpetersuh.com | 886 | 632 | 91 | NA/None (14) | 1. Informative (3); 2. Excellent presentation; 3. Good/Very good/Great/Excellent speaker (2); 4. Knowledgeable (2); 5. Helpful explanations; 6. Interesting; 7. Effective materials; 8. Thank you |
| July 24, 2024: Updates GLP-1 & GIP Agonists for Weight Loss | Melissa Lipari, PharmD, BCACP; mlipari@wayne.edu | 693 | 518 | 73 | NA/None (10) | 1. Excellent speaker (3); 2. Interesting (3); 3. Thank you (3); 4. Very informative (3); 5. Very engaging (3) |
| | Pramodini Kale-Pradhan, PharmD, FCCP, FDSA; pkale@wayne.edu | | | | | |
| | Alison Lobkovich, PharmD; alison.lobkovich@wayne.edu | | | | | |
| August 21, 2024: Optimizing Pharmaceutical Distribution Management: Strategies for Price Transparency and Wholesaler Relations | Mohammed Abdulwahhab; madbulwahhab@mhs.net | 511 | 393 | 68 | NA/None (6) | 1. Great; 2. Good/Very good/Great/Excellent speaker (3); 3. Very nice (2); 4. Interesting |
| | Kyle Brauer; Kyle.Brauer@baycare.org | | | | | 1. He was fine with the part he elaborated on; 2. Interesting |
| September 17, 2024: The Future is Now: The Impact of Artificial Intelligence on Medication Use Safety | Steven Smoke, PharmD, BCIDP; Steven.Smoke@rwjh.org | 772 | 593 | 86 | NA/None (8) | 1. Informative (4); 2. Good; 3. Clear/Concise; 4. Thank you; 5. Interesting; 6. Eloquent; 7. Good/Very good/Great/Excellent speaker (2) |
| | Daniel T. Abazia, PharmD, BCPS, CPPS; dabazia@pharmacy.rutgers.edu | | | | | 1. Good/Very good/Great/Excellent speaker (3); 2. Knowledgeable (3); 3. Clear/Concise (2); 4. Thank you; 5. Interesting; 6. Great |
| October 24, 2024: Multiple Sclerosis: Overview and Advances in Treatment | Mitra Habibi, PharmD; mhabib1@uic.edu | 652 | 504 | 88 | NA/None (10) | 1. Good/Very good/Great/Excellent (3); 2. Clear/Concise; 3. Knowledgeable 4. Informative (2); 5. I learned a lot; 6. Good/Very good/Great/Excellent speaker (2); 7. Soft spoken; 8. Interesting |
| November 20, 2024: Leading Analytics Strategy to Support the Enterprise | David Aguero, PharmD, MSTL, FASHP, FAMA; david.aguero@stjude.org | 660 | 489 | 81 | NA/None (14) | 1. Knowledgeable; 2. Very thorough; 3. Good/Very good/Great/Excellent speaker (3); 4. Great (2); 5. Enjoyed the presentation; 6. Informative (2); 7. Interesting; 8. Keep up the good work; 9. Awesome |
| December 18, 2024: A Gene Therapy Primer for Health Systems | Blake Shay, PharmD, MS; Blake.Shay@baycare.org (blakeshav2014@gmail.com) | 591 | 439 | 71 | None | None |

Pharmacists

| Date and Activity Topic | Speaker(s) | Total # of Registrants | Total # of Participants receiving CE credit | # of Pharmacist s receiving CE credit | Bias, promotion or commercial advertisement? | Comments (number of members with same response in parentheses) |
|---|--|------------------------|---|---------------------------------------|--|---|
| February 7, 2024: NHSN Antibiotic Use Option Data: Implementation and Strategies for Use | Christopher Evans, PharmD; christopher.evans@tn.gov | 660 | 487 | 424 | NA/None (73) | 1. Data extraction, validation, packaging and uploading demo would be helpful; 2. Enthusiastic; 3. Good/Very good/Great/Excellent (12); 4. Good/Very good/Great/Excellent presentation (10); 5. Good/Very good/Great/Excellent speaker (10); 6. Informative (16); 7. Interesting; 8. Knowledgeable (15); 9. Passionate speaker (2); 10. Phenomenal speaker; 11. Thank you (5); 12. Useful information; 13. Good/Very good/Great/Excellent job (3); 14. Very professional; 15. Very thorough; 16. Well done; 17. Well organized |
| April 3, 2024: Sustaining Antimicrobial Stewardship Strategies in Suspected Sepsis | Jeffrey Pearson, PharmD, BCIDP; jpearson@bwh.harvard.edu | 649 | 473 | 405 | NA/None (78) | 1. Appropriate delivery of material; 2. Awesome (2); 3. Brilliant; 4. Clear/Concise (7); 5. Detailed; 6. Easy to follow (4); 7. Eloquent speaker; 8. Engaging; 9. Good/Very good/Great/Excellent (12); 10. Good/Very good/Great/Excellent job (4); 11. Good/Very good/Great/Excellent presentation (10); 12. Good/Very good/Great/Excellent speaker (15); 13. Good description of the guidelines and strategies for sepsis patients; 14. Good work; 15. Helpful (2); 16. Great use of visuals on slides - not too busy; 17. Informative (10); 18. Interesting (2); Knowledgeable (14); 19. Passionate about topic; 20. Professional; 21. Thank you (4); 22. Thorough (3); 23. Very pertinent information; 24. Very well done; 25. Very well put together; 26. Well organized; 27. Wonderful presentation; 28. Wonderful speaker |
| June 4, 2024: Therapeutics for Respiratory Syncytial Virus: How Far We've Come | Christine R. Lockowitz, Pharm.D., BCIDP; Christine.Hanks@bjc.org | 654 | 485 | 417 | NA/None (73) | 1. Clear/Concise (4); 2. Easy to follow; 3. Engaging; 4. Enthusiastic; 5. Good/Very good/Great/Excellent (11); 6. Good/Very good/Great/Excellent presentation (19); 7. Good/Very good/Great/Excellent speaker (11); 8. Good review of RSV vaccines; 9. Good speaking pace; 10. Great job (4); 11. Informative (18); 12. Interesting (2); 13. Knowledgeable (11); 14. Organized (3); 15. Helpful to provide practical recommendations for inpatient administration; 16. Presentation was well delivered; 17. Presented material well (2); 18. Confusing test questions; 19. Thank you; 20. Thorough (4); 21. Extremely helpful to my practice; 22 Very professional |
| August 8, 2024: From Concept to Implementation: Developing an Outpatient Antimicrobial Stewardship Program at Intermountain Health | Whitney Buckel, PharmD, BCIDP; Whitney.Buckel@mail.org | 605 | 441 | 371 | NA/None (50) | 1. Clear/Concise (2); 2. Easy to follow; 3. Engaging; 4. Enjoyable; 5. Enthusiastic; 6. Good/Very good/Great/Excellent (10); 7. Good/Very good/Great/Excellent presentation (9); 8. Good/Very good/Great/Excellent speaker (5); 9. Great job (3); 10. Great topic; 11. Helpful, but the key points could have been more concise; 12. Informative (9); 13. Interesting (2); 14. Knowledgeable (4); 15. Organized (2) |
| | Allan Seibert, MD; allan.seibert@mail.org | | | | | 1. Awesome; 2. Clear/Concise; 3. Energetic; 4. Good/Very good/Great/Excellent (8); 5. Good/Very good/Great/Excellent presentation (7); 6. Great update; 7. Good/Very good/Great/Excellent speaker (3); 8. Difficult to read in table format (2); 9. Good data; 10. Good information; 11. Great job (3); 12. Informative (8); 13. Interactive; 14. Interesting (2); 15. Knowledgeable (5); 16. Thank you; 17. Thorough (2) |
| October 1, 2024: Yes We Can(dida): Approaches to Invasive Candidiasis and Antifungal Stewardship | Caleb Rux, PharmD, BCIDP; calebrux@gmail.com | 635 | 503 | 428 | NA/None (60) | 1. Very well-rounded presentation; 2. Amazing (2); 3. Clear/Concise (5); 4. Could have been more stewardship focused; 5. Easy to understand; 6. Engaging; 7. Enjoyable; 8. Good/Very good/Great/Excellent (13); 9. Good/Very good/Great/Excellent job (3); 10. Good/Very good/Great/Excellent presentation (9); 11. Good/Very good/Great/Excellent speaker (8); 12. Helpful clinical pearls; 13. Informative (11); 14. Interesting; 15. Knowledgeable (11); 16. Organized; 17. Passionate; 18. Professional; 19. Thank you (2); 20. Thorough; 21. Very hard to follow; feedback for answers were very indecisive |
| December 11, 2024: Understanding and Managing C. difficile infection: Pathogenesis, Treatment, and Recurrence Prevention | Emily Drwiega, PharmD, BCIDP, BCPS, AAHIVP; edrwiega@uic.edu | 591 | 542 | 449 | NA/None (74) | 1. Clear/Concise (5); 2. Compelling; 3. Good/Very good/Great/Excellent (12); 4. Good/Very good/Great/Excellent job (2); 5. Good/Very good/Great/Excellent presentation (12); 6. Good/Very good/Great/Excellent speaker (6); 7. Good ideas; 8. Great refresher; 9. Include more questions throughout presentation for more engagement; 10. Informative (14); 11. Insightful; 12. Interesting (2); 13. Knowledgeable (8); 14. Nice presentation; 15. Not detailed enough (3); 16. Well organized (2); 17. Thank you (2); 18. Thorough (2); 19. Unique perspective/experience; 20. Useful, informative pearls |

Pharmacy Technicians

| Date and Activity Topic | Speaker(s) | Total # of Registrants | Total # of Participants receiving CE credit | # of Pharmacy Techs receiving CE credit | Bias, promotion or commercial advertisement? | Comments (number of members with same response in parentheses) |
|---|--|------------------------|---|---|--|--|
| February 7, 2024: NHSN Antibiotic Use Option Data: Implementation and Strategies for Use | Christopher Evans, PharmD; christopher.evans@tn.gov | 660 | 487 | 63 | NA/None (8) | 1. Good/Very good/Great/Excellent speaker (2); 2. Great job (2); 3. Interesting; 4. Professional and informative |
| April 3, 2024: Sustaining Antimicrobial Stewardship Strategies in Suspected Sepsis | Jeffrey Pearson, PharmD, BCIDP; jpearson@bwh.harvard.edu | 649 | 473 | 68 | NA/None (8) | 1. Amazing speaker; 2. Presentation felt more clinical; 3. Excellent job; 4. Excellent speaker; 5. Knowledgeable; 6. Interesting; 7. Concise and detailed |
| June 4, 2024: Therapeutics for Respiratory Syncytial Virus: How Far We've Come | Christine R. Lockowitz, Pharm.D., BCIDP; Christine.Hanks@bjc.org | 654 | 485 | 68 | None | None |
| August 8, 2024: From Concept to Implementation: Developing an Outpatient Antimicrobial Stewardship Program at Intermountain Health | Whitney Buckel, PharmD, BCIDP; Whitney.Buckel@mail.org | 605 | 441 | 70 | NA/None (10) | 1. Amazing; 2. Interesting; 3. Informative (2); 4. Excellent speaker |
| | Allan Seibert, MD; allan.seibert@mail.org | | | | | 1. Amazing; 2. Interesting; 3. Informative (2); 4. Excellent speaker; 5. Knowledgeable |
| October 1, 2024: Yes We Can(dida): Approaches to Invasive Candidiasis and Antifungal Stewardship | Caleb Rux, PharmD, BCIDP; calebrux@gmail.com | 635 | 503 | 75 | NA/None (9) | 1. Excellent speaker (2); 2. Informative; 3. Knowledgeable; 4. Great format; 5. Interesting; 6. Very good; 7. Well done; 8. Provided good learning materials |
| December 11, 2024: Understanding and Managing C. difficile infection: Pathogenesis, Treatment, and Recurrence Prevention | Emily Drwiega, PharmD, BCIDP, BCPS, AAHIVP; edrwiega@uic.edu | 591 | 542 | 93 | NA/None (14) | 1. Informative (3); 2. Good/Very good/Great/Excellent speaker (3); 3. Did well explaining topic and regulating discussion; 4. Interesting; 5. Great presentation; 6. Not detailed enough |

Pharmacists

| Date and Activity Topic | Speaker(s) | Total # of Registrants | Total # of Participants receiving CE credit | # of Pharmacists receiving CE credit | Bias, promotion or commercial advertisement (Pharmacists)? | Comments (number of members with same response in parentheses) |
|---|--|------------------------|---|--------------------------------------|--|---|
| January 10, 2024: Outsourcing to 503Bs: Ingredients, Methods, and Strategies | Kevin N. Hansen, PharmD, MS, BCSCP; kevin.hansen@premierinc.com | 634 | 471 | 409 | NA/None (73) | 1. Clear/Concise (2); 2. Easy to follow; 3. Good/Very good/Great/Excellent (9); 4. Good/Very good/Great/Excellent presentation (10); 5. Good/Very good/Great/Excellent speaker (9); 6. Excellent work; 7. Informative (21); 8. Interesting (3); 9. Knowledgeable (14); 10. OK; 11. Thank you (3); 12. Thorough (3); 13. Timely topic; 14. Very confusing topic but well explained; 15. Very dynamic; 16. Very helpful; 17. Very professional and nice delivery |
| March 7, 2024: What's New with New Technology Add-On Payments? | Alison Schlang, PharmD, MBA, BCPS, FACHE; alison_schlang@premierinc.com | 528 | 383 | 323 | NA/None (45) | 1. Easy to follow; 2. Easy to listen to; 3. Good/Very good/Great/Excellent (7); 4. Good/Very good/Great/Excellent presentation (7); 5. Good/Very good/Great/Excellent speaker (4); 6. Gave a better description of NTAP program; 7. Great job; 8. Great resource; 9. Impressive; 10. Informative (9); 11. Interesting (3); 12. Keep up the good work; 13. Knowledgeable (4); 14. OK; 15. Subject matter was tough; 16. Thank you (3); 17. Thorough; 18. Very organized; 19. Very well done; 20. Very well prepared |
| May 1, 2024: Pharmacy Considerations for the Optimal Utilization of T-cell Engaging Bispecific Antibodies for Hematologic Malignancies | Donald Moore, PharmD, BCPS, BCOP, DPLA, FCCP; Donald.Moore1@atriumhealth.org | 547 | 410 | 342 | NA/None (50) | 1. Awesome; 2. Clear/Concise (2); 3. Easy to understand; 4. Good/Very good/Great/Excellent (9); 5. Good/Very good/Great/Excellent presentation (6); 6. Good/Very good/Great/Excellent speaker (6); 7. Great job (4); 8. Informative (8); 9. Interesting (2); 10. Knowledgeable (8); 11. Thank you; 12. Very engaging |
| July 10, 2024: The Evolution of Pharmacist Responsibility | Peter P. Cohron, BSPHarm, JD; pharmacylawsourc@gmail.com | 689 | 507 | 451 | NA/None (78) | 1. Clear/Concise (3); 2. Enjoyed the presentation immensely; 3. Good/Very good/Great/Excellent (11); 4. Good/Very good/Great/Excellent job (4); 5. Good/Very good/Great/Excellent presentation (14); 6. Good/Very good/Great/Excellent speaker (9); 7. Excellent resource; used relevant case studies; 8. Fun and interactive; 9. Good/very good/Great/Excellent case studies/examples (4); 10. Good pace (2); 11. Great job (3); 12. Presented very well; 13. Informative (17); 14. Interesting (4); 15. Insightful; 16. Keep up the good work; 17. Knowledgeable (12); 18. OK; 19. Technical issue with polling questions was distracting (3); 20. Thank you (3); 21. Unique topic; 22. Very engaging; 23. Very thorough; 24. Was able to identify pharmacists' responsibility in their practice; 25. Well done; 26. Well organized (2) |
| September 24, 2024: Rx Resilience: Health System Strategies to Bolster the Pharmacy Supply Chain and Safeguard Reimbursement | Tyler Sledge, PharmD, BCPS; Tyler.Sledge@rivhs.com | 594 | 459 | 386 | NA/None (51) | 1. Amazing; 2. Clear/Concise (4); 3. Comprehensive; 4. Engaging (2); 5. Good/Very good/Great/Excellent (13); 6. Good/Very good/Great/Excellent presentation (5); 7. Good/Very good/Great/Excellent speaker (5); 8. Great job; 9. Informative (10); 10. Insightful; 11. Interesting; 12. Knowledgeable (2); 13. Presentation was evidence-based |
| | Leah West; Leah.West@rivhs.com | | | | | 1. Amazing; 2. Clear/Concise (4); 3. Easy to follow; 4. Engaging; 5. Enthusiastic; 6. Good/Very good/Great/Excellent (12); 7. Good/Very good/Great/Excellent presentation (3); 8. Good/Very good/Great/Excellent speaker (4); 9. Good pace; 10. Great job; 11. Informative (9); 12. Interesting (4); 13. Organized (2); 14. Very knowledgeable; 15. Very thorough |
| November 12, 2024: Sterile Compounding Compliance Tips for Inspections and Surveys | Patricia C. Kienle, RPh, MPA, BCSCP, FASHP; patricia.kienle@cardinal.com | 826 | 579 | 489 | NA/None (86) | 1. Amazing job; 2. Clear/Concise (4); 3. Comprehensive; 4. Engaging (3); 5. Enlightening; 6. Good/Very good/Great/Excellent (13); 7. Good/Very good/Great/Excellent presentation (12); 8. Good/Very good/Great/Excellent speaker (7); 9. Expert speaker; 10. Fabulous; 11. Great job; 12. Helpful; 13. Informative (18); 14. Interesting; 15. Knowledgeable (12); 16. Nice job; 17. Outstanding speaker; 18. Thank you; 19. Thorough (2); 20. Very energetic; 21. Professional (2); 22. Content was applicable to my scope of practice; 23. Very nice; 24. Very abreast with regulations; 25. Well done; 26. Well organized |

Pharmacy Technicians

| Date and Activity Topic | Speaker(s) | Total # of Registrants | Total # of Participants receiving CE credit | # of Pharmacy Techs receiving CE credit | Bias, promotion or commercial advertisement (Techs)? | Comments (number of members with same response in parentheses) |
|---|--|------------------------|---|---|--|--|
| January 10, 2024: Outsourcing to 503Bs: Ingredients, Methods, and Strategies | Kevin N. Hansen, PharmD, MS, BCSCP; kevin.hansen@premierinc.com | 634 | 471 | 62 | NA/None (8) | 1. Very informative presentation; 2. Good/Very good/Great/Excellent speaker (2); 3. Interesting |
| March 7, 2024: What's New with New Technology Add-On Payments? | Alison Schlang, PharmD, MBA, BCPS, FACHE; alison_schlang@premierinc.com | 528 | 383 | 60 | NA/None (3) | 1. Excellent speaker; 2. Efficient & effective delivery of information; 3. Interesting; 4. Thank you |
| May 1, 2024: Pharmacy Considerations for the Optimal Utilization of T-cell Engaging Bispecific Antibodies for Hematologic Malignancies | Donald Moore, PharmD, BCPS, BCOP, DPLA, FCCP; Donald.Moore1@atriumhealth.org | 547 | 410 | 68 | NA/None (8) | 1. Interesting (2); 2. Thanks; 3. Very good presentation (2); 4. Good/Very good/Great/Excellent speaker (2); 5. Great job; 6. Very informative |
| July 10, 2024: The Evolution of Pharmacist Responsibility | Peter P. Cohron, BSPHarm, JD; pharmacylawsourc@gmail.com | 689 | 507 | 56 | NA/None (8) | 1. Clear/Concise; 2. Interesting; 3. Excellent speaker |
| September 24, 2024: Rx Resilience: Health System Strategies to Bolster the Pharmacy Supply Chain and Safeguard Reimbursement | Tyler Sledge, PharmD, BCPS; Tyler.Sledge@rivhs.com | 594 | 459 | 73 | NA/None (9) | 1. Informative; 2. Insightful; 3. Interesting; 4. Great job; 5. Very good |
| | Leah West; Leah.West@rivhs.com | | | | | 1. Good/Very good/Great/Excellent (2); 2. Knowledgeable; 3. Interesting; 4. Eloquent; 5. Excellent speaker |
| November 12, 2024: Sterile Compounding Compliance Tips for Inspections and Surveys | Patricia C. Kienle, RPh, MPA, BCSCP, FASHP; patricia.kienle@cardinal.com | 826 | 579 | 59 | NA/None (17) | 1. Knowledgeable (3); 2. Wonderful; 3. Excellent speaker; 4. Answers for pre-/post-tests were not covered in this CE; 5. Interesting; 6. Good/Very good/Great/Excellent (2); 7. Nice (2); Very informative; 8. Well done |

Premier, Inc.
Home-Study CE Comments Report - Pharmacists
2024

| Date and Activity Topic | Speaker(s) | Credit Hrs | Total # of Registrants | Total # of Participants receiving CE credit | # of Pharmacists receiving CE credit | Bias, promotion or commercial advertisement? | Objectives that were not met | Comments (number of members with same response in parentheses) |
|---|--|------------|------------------------|---|--------------------------------------|--|---------------------------------------|--|
| 2021 Home-Study CE: A Diverse Healthcare Workforce for America's Present and Future | Regina McClinton, PhD; reginamclinton@icloud.com | 1.0 | 143 | 84 | 49 | NA/None (25) | NA/None (22); Objectives were met (4) | 1. Good job; 2. Good/Very good/Great/Excellent (6); 3. Good pace; 4. Interesting; 5. Good speaker; 6. Effective; 7. Thank you; 8. Great work; 9. Nice job; 10. Informative |
| 2021 Home-Study CE: Achieving and Sustaining USP <800> Compliance | Lilit Smith, PharmD, MBS, BCSCP; lilit@baptisthealth.net | 1.0 | 124 | 81 | 46 | NA/None (13) | NA/None (8) | 1. Wonderful examples; 2. Knowledgeable; 3. Nice job; 4. Detailed; 5. Nicely done; 6. Good review of information; 7. Clear/Concise; 8. Great work |
| 2021 Home-Study CE: COVID-19 Management and Therapeutics – What Lessons Did We Learn? | Debra Goff, PharmD, FIDSA, FCCP; debbie.goff@osumc.edu | 1.0 | 147 | 132 | 65 | NA/None (16) | NA/None (10); Objectives were met (2) | 1. Good/Very good/Great/Excellent presentation (2); 2. Informative (3); 3. Good/Very good/Great/Excellent (4); 4. Clear/Concise |
| 2021 Home-Study CE: Creating a Safe Medication Environment in the Emergency Department | Nicole Acquistio, PharmD, FCCP, BCCCP; Nicole_Acquistio@URMC.Rochester.edu | 1.0 | 486 | 367 | 251 | NA/None (38) | NA/None (25); Objectives were met (6) | 1. Helpful; 2. Couldn't hear speaker; 3. Wonderful (2); 4. Good/Very good/Great/Excellent presentation (4); 5. Great examples (3); 6. Well done (2); 7. Excellent (3); 8. Excellent job; 9. Knowledgeable; 10. Valuable; 11. I enjoyed the speaker; 12. Great speaker, engaging |
| 2021 Home-Study CE: Integrating Biosimilars into Health Systems | Scott Soefje, PharmD, MBA, BCOP, FCCP, FHOPA; Soefje.Scott@mayo.edu | 1.0 | 243 | 136 | 100 | NA/None (8) | NA/None (2); Objectives were met (3) | 1. Very thorough; 2. Excellent presentation; 3. Very knowledgeable; 4. Nice job |
| 2021 Home-Study CE: Laboratory Implementation of CLSI Updates: Recipe for Success | Wendy Szymczak, PhD, D(ABMM), MT(ASCP); wszymcza@montefiore.org | 1.0 | 40 | 21 | 12 | NA/None (4) | NA/None (5) | None |
| 2021 Home-Study CE: Opioid Stewardship | Jennifer Halsey, MS, PharmD, MHA, BCPS; jhalsey@peacehealth.org | 1.0 | 171 | 137 | 98 | NA/None (23) | NA/None (11); objectives were met (2) | 1. Great job; 2. Helpful information; 3. Good/Very good/Great/Excellent presentation (3); 4. Informative (3); 5. Useful information (2); 6. Knowledgeable (2); 7. Easy to understand; 8. Good speaker (2); 9. Excellent; 10. Great work; 11. Enjoyable |
| | Nicholas Quinn, PharmD, BCCCP; nquinn@montefiore.org | | | | | | | 1. Knowledgeable (3); 2. Helpful information; 3. Good/Very good/Great/Excellent presentation (3); 4. Informative (4); 5. Excellent; 6. Great work; 7. Interesting |
| 2021 Home-Study CE: Pharmacy Residency Preceptor Training: Teaching and Research Skills | Ashley Woodruff, PharmD, BCPS; aew7@buffalo.edu | 1.0 | 234 | 154 | 125 | NA/None (10) | NA/None (6) | 1. Knowledgeable; 2. Excellent; 3. Wonderful job |
| | Erin Slazak, PharmD, BCPS, BCACP; emsabria@buffalo.edu | | | | | | | 1. Excellent (2); Great presentation |
| 2021 Home-Study CE: Vancomycin AUC Implementation and Outcomes | Emily L. Heil, PharmD, MS, BCIDP, BCPS, AAHVP; eheil@rx.umaryland.edu | 1.0 | 116 | 58 | 38 | NA/None (12) | NA/None (9); Objectives were met (1) | 1. Excellent speaker; 2. Great presentation (2); 3. Nice job; 4. Informative; 5. Spoke too fast due to time constraints |
| | Erin K. McCreary, PharmD, BCPS, BCIDP; mccrearye3@upmc.edu | | | | | | | 1. Informative (2); 2. Great presentation; 3. Nice job |
| | Victor Chen, PharmD, BCPS, BCIDP; vic002@health.ucsd.edu | | | | | | | 1. Informative (2); 2. Great presentation; 3. Nice job |
| 2022 Home-Study CE: Addressing Pharmacy White-bagging at the State Level: How Providers can Engage to Impact Change | Ken Komorny, PharmD, BCPS; kenneth.komorny@moffitt.org | 1.0 | 193 | 161 | 64 | NA/None (18) | NA/None (12); Objectives were met (3) | 1. Informative; 2. Appreciated the honesty and real-world examples; 3. Great discussion; 4. Great job (2); 5. Easy to follow and understand; 6. Great (2); 7. Helpful; 8. Very eye-opening |
| 2022 Home-Study CE: At Your Disposal: Safe and Compliant Pharmaceutical Waste | Bryan C. McCarthy, Jr., PharmD, MS, MJ, FASHP; BmMcCarthy@Lifespan.org | 1.0 | 207 | 175 | 80 | NA/None (12) | NA/None (9) | 1. Excellent; 2. Great work; 3. Very knowledgeable; 4. Nice job; 5. Informative; 6. Good job (2); 7. Clear/Concise (2) |
| 2022 Home-Study CE: Best Practices for Controlled Substance Diversion Prevention | Amisha Arya, PharmD, BCSCP; amisha.arya@nyulangone.org | 1.0 | 177 | 143 | 71 | NA/None (33) | NA/None (26); Objectives were met (3) | 1. Informative (4); 2. Easy to follow (2); 3. Good/Very good/Great/Excellent (5); 4. Engaging; 5. Effective speaker; 6. Knowledgeable (4); 7. Very insightful (2); 8. Useful ideas for policy implementation; 9. Clear/Concise; 10. Thank you; 11. Good/Great job (3); 12. Excellent slides; 13. Organized and educational |
| 2022 Home-Study CE: Best Practices Utilizing Diabetes Technology Through Transitions of Care | Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES, FADCES, FCCP; dianamisaacs@gmail.com | 1.0 | 126 | 90 | 44 | NA/None (12) | NA/None (7) | 1. Knowledgeable; 2. Well presented; 3. Great presentation; 4. Organized and educational; 5. Fabulous speaker; 6. Nice job; 7. Good job |
| 2022 Home-Study CE: CMS Conditions of Participation: Integration into Accreditation Standards | Patricia C. Kienle, RPh, MPA, BCSCP, FASHP; Patricia.Kienle@cardinalhealth.com | 1.0 | 98 | 69 | 35 | NA/None (9) | NA/None (4) | 1. Well presented; 2. Very interesting information; 3. Excellent; 4. Great presentation; 5. Informative; 6. Good job |
| 2022 Home-Study CE: Establishment and Impact of Clinical Pharmacy Services in an Accountable Care Organization in a Health System | Genevieve Kumapley, PharmD, BCOP; gkumapley@holyname.org | 1.0 | 78 | 71 | 28 | NA/None (3) | NA/None (2) | 1. Very good; 2. Thank you; 3. Great presentation; 4. Good job |
| 2022 Home-Study CE: Implementation of a System-wide Remote Patient Monitoring Program: Increasing Access with Success | Cathleen Mathew, PharmD, CDE, AE-C; cathleen.mathew@mountsinai.org | 1.0 | 94 | 58 | 27 | NA/None (12) | NA/None (4) | 1. Knowledgeable; 2. Well presented; 3. Great presentation; 4. Organized and educational; 5. Fabulous speaker; 6. Nice job; 7. Good job |
| | Ruchi Tiwari, PharmD, MS; ruchi.tiwari@mountsinai.org | | | | | | | 1. Great presentation; 2. Nice job; 3. Good job |
| 2022 Home-Study CE: Improving Nephrotoxin Stewardship by Utilization of Clinical Surveillance | Sandra Kane-Gill, PharmD, MSc, FCCM, FCCP; kane-gill@pitt.edu | 1.0 | 135 | 77 | 42 | NA/None (6) | NA/None (5) | 1. Interesting; 2. Well done; 3. Informative and organized |
| 2022 Home-Study CE: Managing Acute Pain in Opioid Use Disorder | Lee Kral, PharmD, BCPS, CPE; lee-kral@uiowa.edu | 1.0 | 164 | 91 | 60 | NA/None (7) | NA/None (2) | 1. Good speaker; 2. Awesome; 3. Thank you; 4. Very knowledgeable; 5. Clear/Concise; 6. Easy to understand; 7. Excellent; 8. Very informative |
| 2022 Home-Study CE: Medication Safety and Regulatory Compliance in Ambulatory Surgery Centers | Victor Alves, PharmD, BCGP, FASCP; mailto:valves@octariusrx.com | 1.0 | 167 | 143 | 68 | NA/None (14) | NA/None (7) | 1. Good; 2. Engaging; 3. Very helpful—straightforward approach; 4. Knowledgeable; 5. Informative 6. Good job |

Premier, Inc.
Home-Study CE Comments Report - Pharmacists
2024

| Date and Activity Topic | Speaker(s) | Credit Hrs | Total # of Registrants | Total # of Participants receiving CE credit | # of Pharmacists receiving CE credit | Bias, promotion or commercial advertisement? | Objectives that were not met | Comments (number of members with same response in parentheses) |
|--|--|------------|------------------------|---|--------------------------------------|--|--|--|
| 2022 Home-Study CE: Pharmacy Law and Ethics | Keith Yoshizuka, PharmD, MBA, JD, FCSHP; kyoshizu@touro.edu | 1.0 | 146 | 97 | 51 | NA/None (22) | NA/None (11) | 1. Good (2); 2. Seemed to be reading off slides; 3. Useful examples (3); 4. Engaging (2); 5. Informative (3); 6. Direct; 7. Clear/Concise; 8. Good job |
| 2022 Home-Study CE: Strategies to Enhance and Expand Your Antimicrobial Stewardship Program | Yi Guo, PharmD, BCIDP, yiguo@montefiore.org | 1.0 | 118 | 92 | 36 | NA/None (7) | NA/None (3) | 1. Good; 2. Practical information; 3. Very nicely done; added to existing knowledge; 4. Informative (2); 5. Well presented; 6. Good job |
| 2022 Home-Study CE: Successful Management of Formulary Decisions – Controlling Costs Without Compromising Outcomes | Pavel Goriacko, PharmD, MPH, BCPS; pgoriack@montefiore.org | 1.0 | 92 | 82 | 36 | NA/None (18) | NA/None (9); Objectives were met (5) | 1. Great/Excellent job (2); 2. Good (2); 3. Good/Very good/Great/Excellent presentation (2); 4. Valuable information; 5. Informative; 6. Helpful; 7. Organized; 8. Clear/Concise |
| | Janelle Duran, PharmD, BCPS; janelle.duran@commonspirit.org | | | | | | 1. Good/Very good/Great/Excellent presentation (2); 2. Good/Great job (2); 3. Good; 4. Very comprehensive; 5. Informative (3); 6. Easy to follow; 7. Helpful | |
| 2022 Home-Study CE: The Use of SGLT2 Inhibitors for Heart Failure Management | Judy Cheng, PharmD, MPH, FCCP, BCPS, RPh; judy.cheng@mcphs.edu | 1.0 | 115 | 97 | 62 | NA/None (23) | NA/None (7); Objectives were met (1) | 1. Enthusiastic; 2. Very well presented; great balance of information; 3. Clear/Concise (3); 4. Succinct and helpful; 5. Effective speaker; 6. Knowledgeable; 7. Great; 8. Informative; 9. Well organized; 10. Good/Very good/Great/Excellent speaker (2); 11. Excellent presentation; 12. Fantastic job; 13. Well organized |
| 2023 Home-Study CE: 2023 Accreditation Update | Patricia C. Kienle, RPh, MPA, FASHP; Patricia.Kienle@cardinalhealth.com | 1.0 | 162 | 91 | 60 | NA/None (9) | NA/None (4); Objectives were met (1) | 1. Love [speaker]; 2. Great work; 3. Informative (2); 4. Clear/Concise; 5. Succinct speaker; 6. Insightful; 7. Handout material and learning assessment questions could have been more synchronized |
| 2023 Home-Study CE: 2023-2024 Influenza Virus and Vaccine Update | Premier Staff | 1.0 | 119 | 81 | 44 | NA/None (9) | NA/None (3) | None |
| 2023 Home-Study CE: A Joint Commission Primer: It's No Pain at All, When You Follow the Standards | Genevieve Kumapley, PharmD, BCOP; gkumapley@holyname.org | 1.0 | 117 | 96 | 55 | NA/None (14) | NA/None (2); Objectives were met (5) | 1. Excellent (2); 2. Very good speaker; 3. Excellent presentation; 4. Thank you; 5. Organized; 6. Clear/Concise (2); 7. Nice job; 8. Great work; 9. Informative; 10. Knowledgeable (2); 11. Great topic |
| 2023 Home-Study CE: DSCSA and the Standards to Support It | Tracy Nasarenko, BS Accounting, MBA; TNasarenko@gs1us.org | 1.0 | 200 | 106 | 65 | NA/None (9) | NA/None (3) | 1. Some text was difficult to read; 2. Clear/Concise (2); 3. Good |
| 2023 Home-Study CE: Managing Drug Shortages with a Medication Safety Perspective | Kathy Ghomeshi, PharmD, MBA, BCPS, CPPS; kg-rx@ghomeshi.com | 1.0 | 232 | 195 | 112 | NA/None (18) | NA/None (9); Objectives were met (1) | 1. Well organized (2); 2. Excellent presentation; 3. Useful content/references (2); 4. Comprehensive; 5. Great work; 6. Nice job; 7. Knowledgeable (3); 8. Informative; 9. Thank you |
| 2023 Home-Study CE: Optimizing Use of Novel Agents to Treat Multidrug-resistant Gram-negative Infections | Ryan K. Shields, PharmD, MS; shieldsrk@upmc.edu | 1.0 | 151 | 99 | 69 | NA/None (7) | NA/None (3); Objectives were met (1) | 1. Excellent (2); 2. Comprehensive; 3. Easy to follow (2); 4. Clear/Concise (2); 5. Excellent speaker; 6. Great work; 7. Great visuals for future reference; 8. Outstanding; 9. Thoroughly explained |
| 2023 Home-Study CE: Perioperative Antimicrobial Stewardship and Pharmacy's Role | Sara Jordan Hyland, PharmD, BCCCP; Sara.Jordan@ohiohealth.com | 1.0 | 278 | 118 | 81 | NA/None (4) | None | 1. Good/Very good/Great/Excellent (3); 2. Great presentation (2); 3. Great speaker (2); 4. Thank you (2); 5. Informative (2); 6. Really liked topic; 7. Clear/Concise; 8. Knowledgeable and effective speaker |
| 2023 Home-Study CE: Thrombolytics for Acute Ischemic Stroke: Have We Found the Right (Tenecte)Plase in Therapy? | Karen Berger, PharmD, FCCM, BCPS, BCCCP; karenberger7@gmail.com | 1.0 | 380 | 269 | 206 | NA/None (61); Speaker was highlighting tenecteplase over alteplase | NA/None (38); Objectives were met (2) | 1. Awesome; 2. Clear/Concise (2); 3. Easy to understand (2); 4. Effective presentation (2); 5. Enjoyable; 6. Good/Very good/Great/Excellent presentation (3); 7. Good/Very good/Great/Excellent speaker (5); 8. Good/Very good/Great/Excellent (5); 9. Excellent summarization of the trials; 10. Great summary of literature; 11. Informative (6); 12. Knowledgeable (5); 13. Really liked the commentary/call-out on non-disabling minor stroke 2019 guideline change; 14. Thank you; 15. Very comprehensive presentation; 16. Very nice; 17. Very nice job; 18. Very organized (2); 19. Very well done (2); 20. Very well presented |
| 2023 Home-Study CE: Updates in HIV Treatment and Prevention (HIV/AIDS) | Melanie Berry, PharmD, BCACP; mberry2@bidmc.harvard.edu | 1.0 | 193 | 128 | 61 | NA/None (10) | NA/None (6); Objectives were met (2) | 1. Excellent; 2. Great presentation; 3. Should provide an abbreviation key; 4. Well organized |
| 2024 Home-Study CE: Reversal of Direct Factor-Xa Inhibitors, An Evidence Update | Michael P. Gulseth, Pharm. D., BCPS, FMSHP, FASHP; michael.gulseth@sanfordhealth.org | 1.0 | 300 | 161 | 139 | NA/None (4) | None | 1. Knowledgeable; 2. Good/Very good/Great/Excellent presentation (3); 3. Informative; 4. Great job summarizing data |
| 2024 Home-Study CE: 2024-2025 Influenza Virus and Vaccine Update | Premier Staff | 1.0 | 143 | 86 | 71 | NA/None (7) | NA/None (1) | None |

Premier, Inc.
Home-Study CE Comments Report - Pharmacy Technicians
2024

| Date and Activity Topic | Speaker(s) | Credit Hrs | Total # of Registrants | Total # of Participants receiving CE credit | # of Pharmacy Techs receiving CE credit | Bias, promotion or commercial advertisement? | Objectives that were met | Comments (number of members with same response in parentheses) |
|---|--|------------|------------------------|---|---|--|---------------------------------------|--|
| 2021 Homestudy CE: A Diverse Healthcare Workforce for America's Present and Future | Regina McClinton, PhD; reginamclinton@icloud.com | 1.0 | 143 | 84 | 35 | NA/None (13); logo was everywhere | NA/None (13); Objectives were met (1) | 1. Interesting; 2. Good; 3. Awesome |
| 2021 Homestudy CE: Achieving and Sustaining USP <800> Compliance | Lilit Smith, PharmD, MBS, BCSCP; lilits@baptisthealth.net | 1.0 | 124 | 81 | 35 | NA/None (6) | NA/None (2) | 1. Thorough; 2. Clear/Concise; 3. Detailed |
| 2021 Homestudy CE: COVID-19 Management and Therapeutics – What Lessons Did We Learn? | Debra Goff, PharmD, FIDSA, FCCP; debbie.goff@osumc.edu | 1.0 | 147 | 132 | 67 | NA/None (15) | NA/None (9) | 1. Clear/Concise; 2. Nice; 3. Good/Very good/Great/Excellent (2); 4. Excellent communicator |
| 2021 Homestudy CE: Creating a Safe Medication Environment in the Emergency Department | Nicole Acquisto, PharmD, FCCP, BCCCP; Nicole_Acquisto@URMC.Rochester.edu | 1.0 | 486 | 367 | 116 | NA/None (11) | NA/None (10) | 1. Easily understood; 2. Easy to listen to; 3. Comprehensive examples; 4. Informative; 5. Great job; 6. Enjoyed the [presentation]; 7. Helpful |
| 2021 Homestudy CE: Integrating Biosimilars into Health Systems | Scott Soefje, PharmD, MBA, BCOP, FCCP, FHOA; Soefje.Scott@mayo.edu | 1.0 | 243 | 136 | 36 | NA/None (2) | None | None |
| 2021 Homestudy CE: Laboratory Implementation of CLSI Updates: Recipe for Success | Wendy Szymczak, PhD, D(ABMM), MT(ASCP); wszymcza@montefiore.org | 1.0 | 40 | 21 | 9 | NA/None (2) | NA/None (1) | None |
| 2021 Homestudy CE: Opioid Stewardship | Jennifer Halsey, MS, PharmD, MHA, BCPS; jhalsey@peacehealth.org | 1.0 | 171 | 137 | 39 | NA/None (12) | NA/None (7) | 1. Very informative; 2. Awesome |
| | Nicholas Quinn, PharmD, BCCCP; nquinn@montefiore.org | | | | | | | 1. Very informative; 2. Great |
| 2021 Homestudy CE: Pharmacy Residency Preceptor Training: Teaching and Research Skills | Ashley Woodruff, PharmD, BCPS; aew7@buffalo.edu | 1.0 | 234 | 154 | 29 | NA/None (3) | NA/None (2) | 1. Well organized and presented effectively; 2. Provided meaningful subject matter material |
| | Erin Slazak, PharmD, BCPS, BCACP; emsabria@buffalo.edu | | | | | | | 1. Easy to understand |
| 2021 Homestudy CE: Vancomycin AUC Implementation and Outcomes | Emily L. Heil, PharmD, MS, BCIDP, BCPS, AAHVP; eheil@rx.umaryland.edu | 1.0 | 116 | 58 | 20 | NA/None (12) | NA/None (2) | Great job |
| | Erin K. McCreary, PharmD, BCPS, BCIDP; mccrearye3@upmc.edu | | | | | | | |
| | Victor Chen, PharmD, BCPS, BCIDP; vic002@health.ucsd.edu | | | | | | | |
| 2022 Homestudy CE: Addressing Pharmacy White-bagging at the State Level: How Providers can Engage to Impact Change | Ken Komorny, PharmD, BCPS; kenneth.komorny@moffitt.org | 1.0 | 193 | 161 | 97 | NA/None (21) | NA/None (13) | 1. Well done; 2. Great; 3. Great job; 4. Informative (2); 5. Thanks; 6. Great presentation; 7. I enjoyed this CE |
| 2022 Homestudy CE: At Your Disposal: Safe and Compliant Pharmaceutical Waste | Bryan C. McCarthy, Jr., PharmD, MS, MJ, FASHP; BMCCarthy@Lifespan.org | 1.0 | 207 | 175 | 95 | NA/None (16) | NA/None (12) | 1. Very informative; 2. Very knowledgeable; 3. Clear/Concise; 4. Great speaker; 5. Good (2) |
| 2022 Homestudy CE: Best Practices for Controlled Substance Diversion Prevention | Amisha Arya, PharmD, BCSCP; amisha.arya@nyulangone.org | 1.0 | 177 | 143 | 72 | NA/None (18) | NA/None (11) | 1. Great work; 2. Great job; 3. Great presentation; 4. Clear/Concise; 5. Well done |
| 2022 Homestudy CE: Best Practices Utilizing Diabetes Technology Through Transitions of Care | Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES, FADCES, FCCP; dianamisaacs@gmail.com | 1.0 | 126 | 90 | 46 | NA/None (11) | NA/None (4) | 1. Very good; 2. Very informative; 3. Amazing; passionate and very knowledgeable |
| 2022 Homestudy CE: CMS Conditions of Participation: Integration into Accreditation Standards | Patricia C. Kienle, RPh, MPA, BCSCP, FASHP; Patricia.Kienle@cardinalhealth.com | 1.0 | 98 | 69 | 34 | NA/None (4) | NA/None (3) | 1. Interesting |
| 2022 Homestudy CE: Establishment and Impact of Clinical Pharmacy Services in an Accountable Care Organization in a Health System | Genevieve Kumapley, PharmD, BCOP; gkumapley@holyname.org | 1.0 | 78 | 71 | 43 | NA/None (4) | NA/None (5) | 1. Great information; 2. Nice job |
| 2022 Homestudy CE: Implementation of a system-wide remote patient monitoring program: increasing access with success | Cathleen Mathew, PharmD, CDE, AE-C; cathleen.mathew@mountsinai.org | 1.0 | 94 | 58 | 31 | NA/None (3) | NA/None (2) | None |
| | Ruchi Tiwari, PharmD, MS; ruchi.tiwari@mountsinai.org | | | | | | | |
| 2022 Homestudy CE: Improving Nephrotoxin Stewardship by Utilization of Clinical Surveillance | Sandra Kane-Gill, PharmD, MSc, FCCM, FCCP; kane-gill@pitt.edu | 1.0 | 135 | 77 | 35 | NA/None (6) | NA/None (5) | None |
| 2022 Homestudy CE: Managing Acute Pain in Opioid Use Disorder | Lee Kral, PharmD, BCPS, CPE; lee-kral@uiowa.edu | 1.0 | 164 | 91 | 31 | NA/None (6) | NA/None (2) | 1. Good (2); 2. Very informative |
| 2022 Homestudy CE: Medication Safety and Regulatory Compliance in Ambulatory Surgery Centers | Victor Alves, PharmD, BCGP, FASCP; mailto:valves@octariusrx.com | 1.0 | 167 | 143 | 75 | NA/None (15) | NA/None (9); Objectives were met (1) | 1. Good; 2. Clear/Concise; 3. Informative |
| 2022 Homestudy CE: Pharmacy Law and Ethics | Keith Yoshizuka, PharmD, MBA, JD, FCSHP; kyoshizu@touro.edu | 1.0 | 146 | 97 | 46 | NA/None (9) | NA/None (5) | 1. Very good speaker; 2. Clear/Concise; 3. Good |
| 2022 Homestudy CE: Strategies to Enhance and Expand Your Antimicrobial Stewardship Program | Yi Guo, PharmD, BCIDP, yiguo@montefiore.org | 1.0 | 118 | 92 | 56 | None | None | None |
| 2022 Homestudy CE: Successful Management of Formulary Decisions – Controlling Costs Without Compromising Outcomes | Pavel Goriacko, PharmD, MPH, BCPS; pgoriack@montefiore.org | 1.0 | 92 | 82 | 46 | NA/None (14) | NA/None (12) | 1. Good; 2. Great information |
| | Janelle Duran, PharmD, BCPS; janelle.duran@commonspirit.org | | | | | | | 1. Good |
| 2022 Homestudy CE: The Use of SGLT2 Inhibitors for Heart Failure Management | Judy Cheng, PharmD, MPH, FCCP, BCPS, RPh; judy.cheng@mcphs.edu | 1.0 | 115 | 97 | 35 | NA/None (7) | NA/None (4) | 1. No helpful information for techs; 2. Very knowledgeable (2); 3. fast-paced; 4. Clear/Concise |
| 2023 Home-Study CE: 2023 Accreditation Update | Patricia C. Kienle, RPh, MPA, FASHP; Patricia.Kienle@cardinalhealth.com | 1.0 | 162 | 91 | 31 | NA/None (7) | NA/None (3) | 1. Knowledgeable; 2. Clear/Concise; 3. Informative (2) |

Premier, Inc.
Home-Study CE Comments Report - Pharmacy Technicians
2024

| Date and Activity Topic | Speaker(s) | Credit Hrs | Total # of Registrants | Total # of Participants receiving CE credit | # of Pharmacy Techs receiving CE credit | Bias, promotion or commercial advertisement? | Objectives that were <u>not</u> met | Comments (number of members with same response in parentheses) |
|--|--|------------|------------------------|---|---|--|---------------------------------------|---|
| 2023 Home-Study CE: 2023-2024 Influenza Virus and Vaccine Update | Premier Staff | 1.0 | 119 | 81 | 37 | NA/None (5) | None | None |
| 2023 Home-Study CE: A Joint Commission Primer: It's No Pain at All, When You Follow the Standards | Genevieve Kumapley, PharmD, BCOP; gkumapley@holyname.org | 1.0 | 117 | 96 | 41 | NA/None (6) | NA/None (6) | 1. Good (2) |
| 2023 Home-Study CE: DSCSA and the Standards to Support It | Tracy Nasarenko, BS Accounting, MBA; TNasarenko@gs1us.org | 1.0 | 200 | 106 | 41 | NA/None (1) | None | 1. Clear/Concise; 2. Knowledgeable and easy to understand |
| 2023 Home-Study CE: Managing Drug Shortages with a Medication Safety Perspective | Kathy Ghomeshi, PharmD, MBA, BCPS, CPPS; kg-rx@ghomeshi.com | 1.0 | 232 | 195 | 83 | NA/None (16) | NA/None (10); Objectives were met (1) | 1. Thank you; 2. Good/Very good/Great/Excellent (4); 3. Informative; 4. Great presentation |
| 2023 Home-Study CE: Optimizing Use of Novel Agents to Treat Multidrug-resistant Gram-negative Infections | Ryan K. Shields, PharmD, MS; shieldsrk@upmc.edu | 1.0 | 151 | 99 | 30 | NA/None (10) | NA/None (7) | 1. Good (3) |
| 2023 Home-Study CE: Perioperative Antimicrobial Stewardship and Pharmacy's Role | Sara Jordan Hyland, PharmD, BCCCP; Sara.Jordan@ohiohealth.com | 1.0 | 278 | 118 | 37 | NA/None (2) | NA/None (1) | 1. Great (3); 2. Informative |
| 2023 Home-Study CE: Thrombolytics for Acute Ischemic Stroke: Have We Found the Right (Tenecte)Plase in Therapy? | Karen Berger, PharmD, FCCM, BCPS, BCCCP; karenberger7@gmail.com | 1.0 | 380 | 269 | 63 | NA/None (9) | NA/None (8); Objectives were met (1) | 1. Good presentation; 2. Wonderful; 3. Great job; 4. Good; 5. Well prepared; clear/concise |
| 2023 Home-Study CE: Updates in HIV Treatment and Prevention (HIV/AIDS) | Melanie Berry, PharmD, BCACP; mberry2@bidmc.harvard.edu | 1.0 | 193 | 128 | 67 | NA/None (12) | NA/None (8) | 1. Informative; 2. Knowledgeable; 3. Too much unnecessary information; 4. Valuable information; 5. Well prepared; 6. Clear/Concise; 7. Very good presentation |
| 2024 Home-Study CE: Reversal of Direct Factor-Xa Inhibitors, An Evidence Update | Michael P. Gulseth, Pharm. D., BCPS, FMSHP, FASHP; michael.gulseth@sanfordhealth.org | 1.0 | 300 | 161 | 22 | NA/None (2) | NA/None (1) | None |
| 2024 Home-Study CE: 2024-2025 Influenza Virus and Vaccine Update | Premier Staff | 1.0 | 143 | 86 | 15 | NA/None (6) | NA/None (3) | None |

Premier, Inc.
Breakthroughs CE Comments Report
2024

Pharmacists Only

| Date and Activity Topic | Speaker(s) | Total # of Registrants | Total # of Participants receiving CE credit | Bias, promotion or commercial advertisement? | Comments (number of members with same response in parentheses) |
|---|---|------------------------|---|--|---|
| July 24, 2024: Pharm-1: Advancements in Drug Distribution: Blockchain Networking and Centralized Service Model | Brandon McLain; Brandon.Mclain@bhsi.com Thomas Matanich, MBA, PMP; Thomas.Matanich@bhsi.com | 22 | 22 | None | 1. Should provide acronym key; 2. Great |
| July 24, 2024: Pharm-2: Reducing Pharmacy Costs Through Management of Drug Shortages and IV Waste | David Cecere, PharmD, MBA; cecered@wvmedicine.org Marc Phillips, PharmD, CPHQ, 340B ACE; marc.phillips1@wvmedicine.org | 22 | 21 | None | 1. Knowledgeable and provided good advice; easy to follow; 2. Very entertaining and good material Excellent description of methodology and process for waste audit |
| July 24, 2024: Pharm-6: Optimizing Pharmaceutical Distribution Management: Strategies for Price Transparency and Wholesaler Relations | Mohammed Abdulwahhab; madbulwahhab@mhs.net Kyle Brauer; Kyle.Brauer@baycare.org | 26 | 23 | None | (for Dr. Abdulwahhab) 1. Well done; 2. Great speaker, passionate and enthusiastic; an enjoyable and interactive presentation |
| July 25, 2024: LO-2: Work Force Optimization: Strategies and Solutions for Retention Success with Pharmacy Talent | Michael Nnandi; michael.nnadi@harrishealth.org | 1 | 1 | None | None |
| July 25, 2024: Pharm-3: Managing Drug Diversion | Austin Kucher; Austin.kucher@adventhealth.com Karen Hancock; Karen_Hancock@bshsi.org | 25 | 24 | NA/None (1) | Passionate; impressive development of program from scratch Great insight and experience shared |
| July 25, 2024: Pharm-4: My 340BESP Experience | Michael K. Lessard, RPh, MBA, 340B ACE; MLessard@peacehealth.org | 9 | 9 | None | Fun and interactive presentation |
| July 25, 2024: Pharm-5: Optimization of Biosimilar Intake and Patient Access Considerations – Harris Health System Experience | Jessica Njoku, PharmD, MPH, BCPS; jessica.njoku@harrishealth.org | 11 | 8 | None | Very complicated topic; test questions were difficult and slides didn't provide information to complete the test |

Premier, Inc.
Pharmacy Executive Conference, Capstone, Yankee Alliance and Premier Member Meeting CE Comments Reports
2024

2024 Pharmacy Executive Conference CEs

| Date and Activity Topic | Speaker(s) | Total # of Registrants | Total # of Participants receiving CE credit | # of Pharmacy Technicians receiving CE credit | Bias, promotion or commercial advertisement? | Comments (number of members with same response in parentheses) |
|--|--|------------------------|---|---|--|--|
| March 20, 2024: Integrating a Population Health Clinical Pharmacy Program for Management of Early Stage Diabetic Kidney Disease (DKD) at a Metropolitan Health System | Jacqueline Mullakary, PharmD, BCACP, CDCES, AE-C; Jacqueline.Mullakary@mountsina.org | 6 | 6 | - | None | None |
| | Catherine Liu, PharmD, BCPS, BCGP; Catherine.Liu@mountsina.org | | | | | |
| March 20, 2024: The Evolving Nature of Formulary Management – Dealing with High Cost Medications | Fernando Rodriguez, PharmD; fernando_rodriguez@premierinc.com | 6 | 6 | - | None | None |

2024 Capstone CEs

| Date and Activity Topic | Speaker(s) | Total # of Registrants | Total # of Participants receiving CE credit | # of Pharmacy Technicians receiving CE credit | Bias, promotion or commercial advertisement? | Comments (number of members with same response in parentheses) |
|--|--|------------------------|---|---|--|--|
| October 15, 2024: Standardized Education Impact on Medication History Errors in Specialist Practice | Jeffrey Lewis, PharmD, BCPS, BCACP, CDCES; JLewis2@utmck.edu | 7 | 3 | - | NA/None (1) | Well organized, easy to follow and very helpful |
| October 16, 2024: Advancements in Drugs Distribution: Blockchain Networking and Centralized Service Model | Thomas Matanich, MBA, PMP; Thomas.Matanich@bhsi.com | 9 | 4 | - | NA/None (1) | Highly specialized and not pertinent to a small rural hospital; very interesting and super knowledgeable |

2024 Yankee Alliance CEs

| Date and Activity Topic | Speaker(s) | Total # of Registrants | Total # of Participants Receiving CE credit | # of Pharmacists Receiving CE credit | # of Pharmacy Technicians Receiving CE credit | Bias, promotion or commercial advertisement? | Comments (number of members with same response in parentheses) |
|--|---|------------------------|---|--------------------------------------|---|--|--|
| October 22, 2024: An In-Depth Look at Vetting Outsourced Services for IV Admixtures (503B) | Kevin N. Hansen, PharmD, MS, BCSCP; kevin.hansen@premierinc.com | 9 | 7 | 6 | 1 | None | 1. Excellent presentation; 2. Interesting |
| October 23, 2024: Advancements in Drugs Distribution: Blockchain Networking and Centralized Service Model | Thomas Matanich, MBA, PMP; Thomas.Matanich@bhsi.com | 9 | 8 | 7 | 1 | NA/None (1) | 1. Great talk; enhanced my knowledge; 2. Great presentation |

2024 Premier Member Meeting CE

| Date and Activity Topic | Speaker(s) | Total # of Registrants | Total # of Participants receiving CE credit | # of Pharmacists Receiving CE Credit | # of Pharmacy Technicians receiving CE credit | Bias, promotion or commercial advertisement? | Comments (number of members with same response in parentheses) |
|---|---|------------------------|---|--------------------------------------|---|--|--|
| December 8, 2024: DSCSA: Implementation Requirements Post FDA Stabilization Period | Carl Gomberg; carl_gomberg@premierinc.com | 21 | 21 | 21 | - | NA/None (3) | 1. Thank you; 2. Good program/presentation (2); 3. Well done |

Premier, Inc. 2024 Overall CE Activity Rating Averages

| Date and Activity Topic | Speaker(s) | Total # of Registrants | Total # of CE Credit Recipients | Overall CE Activity Rating Averages | |
|---|--|------------------------|---------------------------------|-------------------------------------|--------------|
| CE Activity | | | | | |
| TeleCEs | | | | | |
| | | | | Pharmacists | Techs |
| January 30, 2024: Adalimumab-SOS: Navigating the Market Entry of Adalimumab Biosimilars in the US | Stefanie Cisek, PharmD, BCACP; stefanie.cisek@nm.org | 590 | 459 | 4.39 | 4.40 |
| February 20, 2024: Medication Management of Parkinson's disease (PD) and Sequelae | Jacquelyn Bainbridge PharmD, FCCP; jacci.bainbridge@cuanschutz.edu | 662 | 490 | 4.44 | 4.36 |
| March 20, 2024: What Lies Ahead – A Look at the Biosimilar, Infectious Diseases and Specialty/Oncology Drug Pipeline in 2024-2025 | Liya Davydov, PharmD, BCPS, BCGP; liya_davydov@premierinc.com | 679 | 510 | 4.34 | 4.42 |
| April 24, 2024: Buprenorphine in the Management of Opioid Use Disorder (OUD): Updates on Role in Therapy, Accessibility, and Novel Dosing Strategies | Michael Biglow, PharmD, BCPS, BCPP; mbiglow@pms.org | 682 | 493 | 4.46 | 4.32 |
| May 22, 2024: Cultivating an Inclusive Culture: Managing Difficult Co-Workers Including Yourself | Kevin N. Hansen, PharmD, MS, BCSCP; kevin.hansen@premierinc.com Robert P. Granko, PharmD, MBA, FASHP, FNCAP; rgranko@pennstatehealth.psu.edu | 675 | 492 | 4.47 | 4.31 |
| June 26, 2024: Protecting Our Little Ones! Reducing Medication Errors in Neonates and Pediatrics | Judith Scala, PharmD, BCPPS; JScala@saintpetersuh.com | 886 | 632 | 4.48 | 4.44 |
| July 24, 2024: Updates GLP-1 & GIP Agonists for Weight Loss | Melissa Lipari, PharmD, BCACP; mlipari@wayne.edu Pramodini Kale-Pradhan, PharmD, FCCP, FIDSA; pkale@wayne.edu Alison Lobkovich, PharmD; alison.lobkovich@wayne.edu | 693 | 518 | 4.48 | 4.38 |
| August 21, 2024: Optimizing Pharmaceutical Distribution Management: Strategies for Price Transparency and Wholesaler Relations | Mohammed Abdulwahhab; madbulwahhab@mhs.net Kyle Brauer; Kyle.Brauer@baycare.org | 511 | 393 | 4.40 | 4.29 |
| September 17, 2024: The Future is Now: The Impact of Artificial Intelligence on Medication Use Safety | Steven Smoke, PharmD, BCIDP; Steven.Smoke@rwjrh.org Daniel T. Abazia, PharmD, BCPS, CPPS; dabazia@pharmacy.rutgers.edu | 772 | 593 | 4.42 | 4.41 |
| October 24, 2024: Multiple Sclerosis: Overview and Advances in Treatment | Mitra Habibi, PharmD; mhabibi1@uic.edu | 652 | 504 | 4.44 | 4.36 |
| November 20, 2024: Leading Analytics Strategy to Support the Enterprise | David Aguero, PharmD, MSTL, FASHP, FAMILA; david.aguero@stjude.org | 660 | 489 | 4.42 | 4.39 |
| December 18, 2024: A Gene Therapy Primer for Health Systems | Blake Shay, PharmD, MS; Blake.Shay@baycare.org (blakeshav2014@gmail.com) | 591 | 439 | 4.39 | 4.48 |
| ASFs | | | | | |
| February 7, 2024: NHSN Antibiotic Use Option Data: Implementation and Strategies for Use | Christopher Evans, PharmD; christopher.evans@tn.gov | 660 | 487 | 4.39 | 4.37 |
| April 3, 2024: Sustaining Antimicrobial Stewardship Strategies in Suspected Sepsis | Jeffrey Pearson, PharmD, BCIDP; jpearson@bwh.harvard.edu | 649 | 473 | 4.52 | 4.41 |
| June 4, 2024: Therapeutics for Respiratory Syncytial Virus: How Far We've Come | Christine R. Lockowitz, PharmD., BCIDP; Christine.Hanks@bjc.org | 654 | 485 | 4.47 | 4.25 |
| August 8, 2024: From Concept to Implementation: Developing an Outpatient Antimicrobial Stewardship Program at Intermountain Health | Whitney Buckel, PharmD, BCIDP; Whitney.Buckel@gmail.com Allan Seibert, MD; allan.seibert@imail.org | 605 | 441 | 4.42 | 4.33 |
| October 1, 2024: Yes We Can(dida): Approaches to Invasive Candidiasis and Antifungal Stewardship | Caleb Rux, PharmD, BCIDP; calebrux@gmail.com | 635 | 503 | 4.51 | 4.34 |
| December 11, 2024: Understanding and Managing C. difficile infection: Pathogenesis, Treatment, and Recurrence Prevention | Emily Drwiega, PharmD, BCIDP, BCPS, AAHIVP; edrwiega@uic.edu | 591 | 542 | 4.47 | 4.42 |
| PPFs | | | | | |
| January 10, 2024: Outsourcing to 503Bs: Ingredients, Methods, and Strategies | Kevin N. Hansen, PharmD, MS, BCSCP; kevin.hansen@premierinc.com | 634 | 471 | 4.45 | 4.49 |
| March 7, 2024: What's New with New Technology Add-On Payments? | Alison Schlang, PharmD, MBA, BCPS, FACHE; alison_schlang@premierinc.com | 528 | 383 | 4.36 | 4.35 |
| May 1, 2024: Pharmacy Considerations for the Optimal Utilization of T-cell Engaging Bispecific Antibodies for Hematologic Malignancies | Donald Moore, PharmD, BCIDP, BCOP, DPLA, FCCP; Donald.Moore1@atriumhealth.org | 547 | 410 | 4.42 | 4.31 |
| July 10, 2024: The Evolution of Pharmacist Responsibility | Peter P. Cohron, BSPHarm, JD; pharmacylawsource@gmail.com | 689 | 507 | 4.50 | 4.38 |
| September 24, 2024: Rx Resilience: Health System Strategies to Bolster the Pharmacy Supply Chain and Safeguard Reimbursement | Tyler Sledge, PharmD, BCPS; Tyler.Sledge@rivhs.com Leah West; Leah.West@rivhs.com | 594 | 459 | 4.40 | 4.42 |
| November 12, 2024: Sterile Compounding Compliance Tips for Inspections and Surveys | Patricia C. Kienle, RPH, MPA, BCSCP, FASHP; patricia.kienle@cardinal.com | 826 | 579 | 4.43 | 4.32 |
| Breakthroughs CE's | | | | | |
| July 24, 2024: Pharm-1: Advancements in Drug Distribution: Blockchain Networking and Centralized Service Model | Brandon McLain; Brandon.Mclain@bhsi.com Thomas Matanich, MBA, PMP; Thomas.Matanich@bhsi.com | 22 | 22 | 4.65 | - |
| July 24, 2024: Pharm-2: Reducing Pharmacy Costs Through Management of Drug Shortages and IV Waste | David Cecere, PharmD, MBA; cecered@wvmedicine.org Marc Phillips, PharmD, CPHQ, 340B ACE; marc.phillips1@wvmedicine.org | 22 | 21 | 4.67 | - |
| July 24, 2024: Pharm-6: Optimizing Pharmaceutical Distribution Management: Strategies for Price Transparency and Wholesaler Relations | Mohammed Abdulwahhab; madbulwahhab@mhs.net Kyle Brauer; Kyle.Brauer@baycare.org | 26 | 23 | 4.63 | - |
| July 25, 2024: LO-2: Work Force Optimization: Strategies and Solutions for Retention Success with Pharmacy Talent | Michael Nnandi; michael.nnadi@harrishealth.org | 1 | 1 | 5.00 | - |
| July 25, 2024: Pharm-3: Managing Drug Diversion | Austin Kucher; Austin.kucher@adventhealth.com Karen Hancock; Karen_Hancock@bhsi.org | 25 | 24 | 4.68 | - |
| July 25, 2024: Pharm-4: My 340BESP Experience | Michael K. Lessard, RPH, MBA, 340B ACE; MLessard@peacehealth.org | 9 | 9 | 4.68 | - |
| July 25, 2024: Pharm-5: Optimization of Biosimilar Intake and Patient Access Considerations – Harris Health System Experience | Jessica Njoku, PharmD, MPH, BCPS; jessica.njoku@harrishealth.org | 11 | 8 | 4.60 | - |
| Capstone CE's | | | | | |
| October 15, 2024: Standardized Education Impact on Medication History Errors in Specialist Practice | Jeffrey Lewis, PharmD, BCPS, BCACP, CDCES; JLewis2@utmck.edu | 7 | 3 | 4.75 | - |
| October 16, 2024: Advancements in Drugs Distribution: Blockchain Networking and Centralized Service Model | Thomas Matanich, MBA, PMP; Thomas.Matanich@bhsi.com | 9 | 4 | 4.78 | - |
| Yankee Alliance CE's | | | | | |
| October 22, 2024: An In-Depth Look at Vetting Outsourced Services for IV Admixtures (503B) | Kevin N. Hansen, PharmD, MS, BCSCP; kevin.hansen@premierinc.com | 9 | 7 | 4.92 | 5.00 |
| October 23, 2024: Advancements in Drugs Distribution: Blockchain Networking and Centralized Service Model | Thomas Matanich, MBA, PMP; Thomas.Matanich@bhsi.com | 9 | 8 | 4.80 | 5.00 |

Premier, Inc.

2024 Overall CE Activity Rating Averages

| Date and Activity Topic | Speaker(s) | Total # of Registrants | Total # of CE Credit Recipients | Overall CE Activity Rating Averages | |
|---|--|------------------------|---------------------------------|-------------------------------------|------|
| CE Activity | | | | | |
| Premier Member Meeting CEs | | | | | |
| December 8, 2024: DSCSA: Implementation Requirements Post FDA Stabilization Period | Carl Gomberg; carl_gomberg@premierinc.com | 21 | 21 | 4.65 | - |
| Pharmacy Executives Conference CEs | | | | | |
| March 20, 2024: Integrating a Population Health Clinical Pharmacy Program for Management of Early Stage Diabetic Kidney Disease (DKD) at a Metropolitan Health System | Jacqueline Mullakary, PharmD, BCACP, CDCES, AE-C; Jacqueline.Mullakary@mountsinai.org Catherine Liu, PharmD, BCPS, BCGP; Catherine.Liu@mountsinai.org | 6 | 6 | 5.00 | - |
| March 20, 2024: The Evolving Nature of Formulary Management – Dealing with High Cost Medications | Fernando Rodriguez, PharmD; fernando_rodriguez@premierinc.com | 6 | 6 | 5.00 | - |
| Home Study CEs | | | | | |
| 2021 Homestudy CE: A Diverse Healthcare Workforce for America's Present and Future | Regina McClinton, PhD, reginamccclinton@icloud.com | 143 | 84 | 4.50 | 4.29 |
| 2021 Homestudy CE: Achieving and Sustaining USP <800> Compliance | Lilit Smith, PharmD, MBS, BCSCP; lilit@baptisthealth.net | 124 | 81 | 4.53 | 4.36 |
| 2021 Homestudy CE: COVID-19 Management and Therapeutics – What Lessons Did We Learn? | Debra Goff, PharmD, FIDSA, FCCP; debbie.goff@osumc.edu | 147 | 132 | 4.52 | 4.36 |
| 2021 Homestudy CE: Creating a Safe Medication Environment in the Emergency Department | Nicole Acquisto, PharmD, FCCP, BCCCP; Nicole_Acquisto@URMC.Rochester.edu | 486 | 367 | 4.61 | 4.44 |
| 2021 Homestudy CE: Integrating Biosimilars into Health Systems | Scott Soefje, PharmD, MBA, BCOP, FCCP, FHOPA; Soefje.Scott@mayo.edu | 243 | 136 | 4.61 | 4.52 |
| 2021 Homestudy CE: Laboratory Implementation of CLSI Updates: Recipe for Success | Wendy Szymczak, PhD, D(ABMM), MT(ASCP); wszymcza@montefiore.org | 40 | 21 | 4.38 | 4.46 |
| 2021 Homestudy CE: Opioid Stewardship | Jennifer Halsey, MS, PharmD, MHA, BCPS; jhalsey@peacehealth.org Nicholas Quinn, PharmD, BCCCP; nquinn@montefiore.org | 171 | 137 | 4.56 | 4.30 |
| 2021 Homestudy CE: Pharmacy Residency Preceptor Training: Teaching and Research Skills | Ashley Woodruff, PharmD, BCPS; aew7@buffalo.edu Erin Slazak, PharmD, BCPS, BCACP; emsabria@buffalo.edu | 234 | 154 | 4.49 | 4.55 |
| 2021 Homestudy CE: Vancomycin AUC Implementation and Outcomes | Emily L. Heil, PharmD, MS, BCIDP, BCPS, AAHVP; ehell@rx.umaryland.edu Erin K. McCreary, PharmD, BCPS, BCIDP; mccrearye3@upmc.edu Victor Chen, PharmD, BCPS, BCIDP; vic002@health.ucsd.edu | 116 | 58 | 4.52 | 4.40 |
| 2022 Homestudy CE: Addressing Pharmacy White-bagging at the State Level: How Providers can Engage to Impact Change | Ken Komorny, PharmD, BCPS; kenneth.komorny@moffitt.org | 193 | 161 | 4.66 | 4.32 |
| 2022 Homestudy CE: At Your Disposal: Safe and Compliant Pharmaceutical Waste | Bryan C. McCarthy, Jr., PharmD, MS, MJ, FASHP; BMcCarthy@Lifespan.org | 207 | 175 | 4.57 | 4.40 |
| 2022 Homestudy CE: Best Practices for Controlled Substance Diversion Prevention | Amisha Arya, PharmD, BCSCP; amisha.arya@nyulangone.org | 177 | 143 | 4.56 | 4.38 |
| 2022 Homestudy CE: Best Practices Utilizing Diabetes Technology Through Transitions of Care | Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES, FADCES, FCCP; dianamisaacs@gmail.com | 126 | 90 | 4.59 | 4.45 |
| 2022 Homestudy CE: CMS Conditions of Participation: Integration into Accreditation Standards | Patricia C. Kienle, RPh, MPA, BCSCP, FASHP; Patricia.Kienle@cardinalhealth.com | 98 | 69 | 4.63 | 4.50 |
| 2022 Homestudy CE: Establishment and Impact of Clinical Pharmacy Services in an Accountable Care Organization in a Health System | Genevieve Kumapley, PharmD, BCOP; gkumapley@holyname.org | 78 | 71 | 4.62 | 4.49 |
| 2022 Homestudy CE: Implementation of a System-Wide Remote Patient Monitoring Program: Increasing Access with Success | Cathleen Mathew, PharmD, CDE, AE-C; cathleen.mathew@mountsinai.org Ruchi Tiwari, PharmD, MS; ruchi.tiwari@mountsinai.org | 94 | 58 | 4.59 | 4.55 |
| 2022 Homestudy CE: Improving Nephrotoxin Stewardship by Utilization of Clinical Surveillance | Sandra Kane-Gill, PharmD, MSc, FCCM, FCCP; kane-gill@pitt.edu | 135 | 77 | 4.58 | 4.45 |
| 2022 Homestudy CE: Managing Acute Pain in Opioid Use Disorder | Lee Kral, PharmD, BCPS, CPE; lee-kral@uiowa.edu | 164 | 91 | 4.64 | 4.66 |
| 2022 Homestudy CE: Medication Safety and Regulatory Compliance in Ambulatory Surgery Centers | Victor Alves, PharmD, BCGP, FASCP; mailto:valves@octariusrx.com | 167 | 143 | 4.54 | 4.44 |
| 2022 Homestudy CE: Pharmacy Law and Ethics | Keith Yoshizuka, PharmD, MBA, JD, FCSHP; kyoshizu@touro.edu | 146 | 97 | 4.64 | 4.47 |
| 2022 Homestudy CE: Strategies to Enhance and Expand Your Antimicrobial Stewardship Program | Yi Guo, PharmD, BCIDP, yigu@montefiore.org | 118 | 92 | 4.64 | 4.67 |
| 2022 Homestudy CE: Successful Management of Formulary Decisions – Controlling Costs Without Compromising Outcomes | Pavel Goriacko, PharmD, MPH, BCPS; pgoriack@montefiore.org Janelle Duran, PharmD, BCPS; janelle.duran@commonsprout.org | 92 | 82 | 4.57 | 4.57 |
| 2022 Homestudy CE: The Use of SGLT2 Inhibitors for Heart Failure Management | Judy Cheng, PharmD, MPH, FCCP, BCPS, RPh; judy.cheng@mcphs.edu | 115 | 97 | 4.63 | 4.37 |
| 2023 Home-Study CE: 2023 Accreditation Update | Patricia C. Kienle, RPh, MPA, FASHP; Patricia.Kienle@cardinalhealth.com | 162 | 91 | 4.53 | 4.45 |
| 2023 Home-Study CE: 2023-2024 Influenza Virus and Vaccine Update | Premier Staff | 119 | 81 | 4.66 | 4.56 |
| 2023 Home-Study CE: A Joint Commission Primer: It's No Pain at All, When You Follow the Standards | Genevieve Kumapley, PharmD, BCOP; gkumapley@holyname.org | 117 | 96 | 4.54 | 4.38 |
| 2023 Home-Study CE: DSCSA and the Standards to Support It | Tracy Nasarenko, BS Accounting, MBA; TNasarenko@gs1us.org | 200 | 106 | 4.50 | 4.38 |
| 2023 Home-Study CE: Managing Drug Shortages with a Medication Safety Perspective | Kathy Ghomeshi, PharmD, MBA, BCPS, CPPS; kg-rx@ghomeshi.com | 232 | 195 | 4.59 | 4.48 |
| 2023 Home-Study CE: Optimizing Use of Novel Agents to Treat Multidrug-resistant Gram-negative Infections | Ryan K. Shields, PharmD, MS; shieldsrk@upmc.edu | 151 | 99 | 4.67 | 4.49 |
| 2023 Home-Study CE: Perioperative Antimicrobial Stewardship and Pharmacy's Role | Sara Jordan Hyland, PharmD, BCCCP; Sara.Jordan@ohiohealth.com | 278 | 118 | 4.67 | 4.18 |
| 2023 Home-Study CE: Thrombolytics for Acute Ischemic Stroke: Have We Found the Right (Tenece)Place in Therapy? | Karen Berger, PharmD, FCCM, BCPS, BCCCP; karenberger7@gmail.com | 380 | 269 | 4.63 | 4.45 |
| 2023 Home-Study CE: Updates in HIV Treatment and Prevention (HIV/AIDS) | Melanie Berry, PharmD, BCACP; mberry2@bidmc.harvard.edu | 193 | 128 | 4.61 | 4.38 |
| 2024 Home-Study CE: Reversal of Direct Factor-Xa Inhibitors, An Evidence Update | Michael P. Gulseth, Pharm. D., BCPS, FMSHP, FASHP; michael.gulseth@sanfordhealth.org | 300 | 161 | 4.63 | 4.46 |
| 2024 Home-Study CE: 2024-2025 Influenza Virus and Vaccine Update | Premier Staff | 143 | 86 | 4.68 | 4.59 |